var title_f38_47_39664="Conjunctiva anatomy PI";
var content_f38_47_39664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F81619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F81619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Anatomy of the eye",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39664=[""].join("\n");
var outline_f38_47_39664=null;
var title_f38_47_39665="HRCT giant bulla";
var content_f38_47_39665=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    HRCT giant bulla",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    HRCT image of a giant bulla with adjacent area of compressed pulmonary parenchyma (see arrow).",
"    <div class=\"footnotes\">",
"     HRCT: high resolution computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Fernando J. Martinez, MD, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39665=[""].join("\n");
var outline_f38_47_39665=null;
var title_f38_47_39666="PDA color Doppler echo I";
var content_f38_47_39666=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Color doppler echocardiograph of patent ductus arteriosus from parasternal short axis view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The two-dimensional echocardiogram, with color flow Doppler, recorded from the parasternal short axis view, shows blood flow through a patent ductus arteriosus (arrow).",
"    <div class=\"footnotes\">",
"     Ao: ascending aorta; MPA: main pulmonary artery; RPA: right pulmonary artery; DAo: descending aorta.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Doyle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39666=[""].join("\n");
var outline_f38_47_39666=null;
var title_f38_47_39667="Periph nodule sampling II";
var content_f38_47_39667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Endobronchial ultrasound (EBUS) peripheral nodule sampling II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 491px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) The radial probe is placed in a guide sheath and then both are advanced through the bronchoscope until they reach&nbsp;the airway. B) The radial probe and guide sheath are advanced until the peripheral pulmonary nodule is visualized. C) The probe is removed, leaving the guide sheath in position. D) Biopsy forceps or a bronchial brush are inserted through the guide sheath and the nodule is sampled.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39667=[""].join("\n");
var outline_f38_47_39667=null;
var title_f38_47_39668="Porcelain gallbladder";
var content_f38_47_39668=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Porcelain gallbladder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39668/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39668/contributors\">",
"     Shyam Varadarajulu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39668/contributors\">",
"     Salam F Zakko, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39668/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39668/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39668/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39668/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39668/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/47/39668/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porcelain gallbladder is an uncommon manifestation of chronic cholecystitis, characterized by intramural calcification of the gallbladder wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/1\">",
"     1",
"    </a>",
"    ]. The term \"porcelain gallbladder\" is used to describe the bluish discoloration and brittle consistency of the gallbladder wall seen in this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/2\">",
"     2",
"    </a>",
"    ]. The diagnosis is usually suggested by an abdominal x-ray revealing an incidental calcified lesion in the region of the gallbladder. Patients with a porcelain gallbladder are often asymptomatic, but are at increased risk for the development of gallbladder carcinoma, which has a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, the possibility of a porcelain gallbladder should always be considered in the differential diagnosis of calcified right upper quadrant abdominal lesions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15082?source=see_link\">",
"     \"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK OF MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of a calcified gallbladder at autopsy ranges from 0.06 to 0.08 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/3\">",
"     3",
"    </a>",
"    ]. It is more common in females than in males, with a ratio of 5:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/4\">",
"     4",
"    </a>",
"    ]. The mean age at presentation varies from 38 to 70 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/4\">",
"     4",
"    </a>",
"    ]. The risk of gallbladder cancer in patients with porcelain gallbladder is unclear, with reported rates ranging from 0 to 62 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/2,3,5-8\">",
"     2,3,5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review of eight series that included 60,665 patients who underwent cholecystectomy, 140 (0.2 percent) had porcelain gallbladder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/7\">",
"     7",
"    </a>",
"    ]. Of those with porcelain gallbladder, 21 (15 percent) had gallbladder cancer. However, the authors note that the high rates of gallbladder cancer were seen primarily in older studies. Among the 85 patients with porcelain gallbladder from studies reported between 2001 and 2011, gallbladder cancer was seen in 2 (2.3 percent; range 0 to 5 percent for the individual studies).",
"   </p>",
"   <p>",
"    The pattern of calcification may be particularly important in predicting which patients are at increased risk for gallbladder cancer. Patients with selective mucosal calcification or incomplete calcification of the gallbladder wall appear to be at higher risk for gallbladder cancer compared with those in whom the gallbladder wall is completely calcified (complete type) (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Ultrasonography'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a series of 44 patients with gallbladder calcification who underwent cholecystectomy, 17 had complete intramural calcification, and 27 had selective (incomplete) mucosal calcification [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/6\">",
"       6",
"      </a>",
"      ]. Gallbladder cancer was present in two of the patients with selective mucosal calcification (7 percent) and in none of the patients with complete calcification.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a second series that included 17 patients who underwent surgery, gallbladder cancer was observed in none of the 7 patients with complete calcification compared with of 5 of 10 patients (50 percent) with incomplete calcification [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/9\">",
"       9",
"      </a>",
"      ]. This observation is understandable since gallbladder carcinoma is mucosal in origin. Patients with the complete type of porcelain gallbladder have total loss of the mucosa so that there is very little chance to develop gallbladder cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of gallbladder wall calcification remains controversial. Porcelain gallbladder is associated with cholelithiasis in more than 95 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/5\">",
"     5",
"    </a>",
"    ]. It has been suggested that the gallbladder wall injury results from chronic irritation by gallstones. Some authors speculate that cystic duct obstruction leads to bile stagnation within the gallbladder followed by mucosal precipitation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    salts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/5\">",
"     5",
"    </a>",
"    ]. Others regard calcification as the natural progression of chronic inflammation resulting in scarring, hyalinization, and deposition of lime salts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disease can be seen in two histologic forms. In one type, there is a broad continuous band of calcification within the muscularis that appears radiologically as large plaque-like areas. The second type is characterized by multiple punctate calcifications in the glandular spaces of the mucosa, appearing radiologically as mostly granular calcifications (",
"    <a class=\"graphic graphic_picture graphicRef70858 \" href=\"mobipreview.htm?40/45/41685\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common type of malignancy associated with porcelain gallbladder is adenocarcinoma, which is seen in nearly 80 percent of patients with porcelain gallbladder who develop gallbladder cancer. Squamous cell carcinoma and adenosquamous carcinoma have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15082?source=see_link\">",
"     \"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, patients are often asymptomatic, but occasionally present with biliary type pain. Rarely, the gallbladder may be palpable as a firm, nontender mass in the right upper quadrant.",
"   </p>",
"   <p>",
"    The lesion is usually discovered incidentally on a plain abdominal roentgenogram. The radiologist should alert the clinician to the diagnosis because of the risk of gallbladder carcinoma. A computerized tomogram or ultrasound should then be performed to confirm the diagnosis. The final confirmatory diagnosis is usually made by histopathology after cholecystectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Plain abdominal roentgenogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain abdominal x-rays may reveal curvilinear or rim-like calcifications in the gallbladder wall (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80792 \" href=\"mobipreview.htm?35/0/35840\">",
"     image 1",
"    </a>",
"    ). Gallstones may occasionally be visible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/3\">",
"     3",
"    </a>",
"    ]. Similar x-ray findings can also be seen if the gallbladder is full of bile that is supersaturated with calcium salts (\"milk of calcium bile\") or due to calcifications in gallstones, renal cysts, chest wall masses, and degenerative cystic lesions of the pancreas and adrenal gland. Hence, other imaging modalities such as ultrasonography or computerized tomography are needed to positively identify the gallbladder and confirm the location of calcifications within the gallbladder wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Computerized tomogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of porcelain gallbladder is rarely missed on computed tomography (CT) of the abdomen. The gallbladder wall appears as a calcified rim with a dark central bile-filled region (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60124 \" href=\"mobipreview.htm?31/36/32321\">",
"     image 2",
"    </a>",
"    ). In patients with associated gallbladder cancer, pericholecystic masses may be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, milk of calcium bile appears as one solid calcified mass, while gallstones without porcelain gallbladder appear as calcifications in the center of the gallbladder but sparing the gallbladder wall. Calcifications in other organs or tumors can also be identified by CT scan based upon their anatomic spatial relationships.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three distinct sonographic patterns were described in a series of nine patients who had a porcelain gallbladder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type I &ndash; A hyperechoic semilunar appearance with posterior acoustic shadowing (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80835 \" href=\"mobipreview.htm?10/2/10273\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Type II &ndash; A biconvex curvilinear echogenic appearance with acoustic shadowing",
"     </li>",
"     <li>",
"      Type III &ndash; Irregular clumps of echoes with posterior acoustic shadowing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A simplified classification was subsequently suggested based upon the ultrasound and histopathological findings of 30 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/9\">",
"     9",
"    </a>",
"    ]. Two patterns were recognized:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete type &ndash; In which the gallbladder wall is completely replaced by dense fibrosis or calcification. Calcification is so severe that the mucosal epithelium is peeled off. The complete type corresponded to the type I ultrasound pattern described above.",
"     </li>",
"     <li>",
"      Incomplete type &ndash; Calcification of the gallbladder wall is milder in these patients and there is incomplete exfoliation of the mucosal epithelium. This incomplete type corresponded to the type II and III patterns described above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the risk of gallbladder cancer, porcelain gallbladder has generally been seen as an indication for cholecystectomy, even in asymptomatic patients. As discussed above, the reported incidence of gallbladder carcinoma in patients with porcelain gallbladder is highly variable, with a systematic review suggesting that the risk is low based on more recent studies. This has led some authors to suggest that patients with porcelain gallbladder be observed, with surgery being reserved for those with conventional indications for cholecystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. However, others have challenged this recommendation, noting that the rate of gallbladder cancer seen in more recent studies (2 to 3 percent) is high enough to justify prophylactic cholecystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/12\">",
"     12",
"    </a>",
"    ]. Those authors also note that the majority of patients with porcelain gallbladder are symptomatic (and thus have conventional indications for cholecystectomy). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15082?source=see_link\">",
"     \"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology and risk of malignancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Our approach takes into account the pattern of calcification, since small series suggest an increased risk of cancer in patients with selective mucosal calcification or incomplete mural calcification, but not in those with complete mural calcification. Therefore, until additional data become available, we suggest surgery for patients with selective mucosal calcification or incomplete mural calcification, regardless of symptoms, provided they are good surgical candidates.",
"   </p>",
"   <p>",
"    We refer patients with complete mural calcification for cholecystectomy if they are symptomatic. Among patients with complete mural calcification who are asymptomatic, particularly those who are young or who have good functional status, we consider prophylactic cholecystectomy, despite limited data regarding the true risk of gallbladder cancer in such patients, because the prognosis for gallbladder cancer is grave. For patients with significant comorbidities and borderline health status, surveillance imaging and clinical follow-up may be an appropriate strategy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology and risk of malignancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Open rather than laparoscopic cholecystectomy was previously recommended in these patients because the gallbladder wall is very thick, fibrotic, and calcified, making it potentially difficult to grab by forceps and dissect out [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/13\">",
"     13",
"    </a>",
"    ]. However, laparoscopic cholecystectomy may be possible in patients with a long cystic duct and biliary anatomy that is well defined preoperatively by ERCP or intraoperative cholangiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/14\">",
"     14",
"    </a>",
"    ]. One report of 13 patients suggested that laparoscopic cholecystectomy was a reasonable option in patients classified as having type I porcelain gallbladder by ultrasonography as described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39668/abstract/15\">",
"     15",
"    </a>",
"    ]. Gallbladder cancer was not seen in any of the ten patients classified as having type 1 porcelain gallbladder compared to one of three patients classified as having type 2 porcelain gallbladder. Thus, preoperative ultrasound may have an important role in guiding the operative management of patients with porcelain gallbladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Porcelain gallbladder is an uncommon manifestation of chronic cholecystitis, characterized by intramural calcification of the gallbladder wall. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of gallbladder carcinoma in patients with a calcified gallbladder is approximately 2 to 3 percent. Small series suggest that an increased risk of cancer is confined to patients with selective mural calcification or incomplete calcification, though additional data are needed to confirm these findings. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk of malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common type of malignancy associated with porcelain gallbladder is adenocarcinoma, which is seen in nearly 80 percent of patients with porcelain gallbladder who develop gallbladder cancer. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The lesion is usually discovered incidentally on a plain abdominal roentgenogram. A computerized tomogram or ultrasound should then be performed to confirm the diagnosis. The final confirmatory diagnosis is usually made by histopathology after cholecystectomy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our approach takes into account the pattern of calcification, since small series suggest an increased risk of cancer in patients with selective mucosal calcification or incomplete mural calcification, but not in those with complete mural calcification. Until additional data become available, we suggest surgery for patients with selective mucosal calcification or incomplete mural calcification, regardless of symptoms, provided they are good surgical candidates (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We refer patients with complete mural calcification for cholecystectomy if they are symptomatic. Because the prognosis for gallbladder cancer is grave, we also discuss prophylactic cholecystectomy with asymptomatic patients who are young or have good functional status, despite limited data regarding the true risk of gallbladder cancer in such patients. For patients with major comorbidity and borderline health status, clinical follow-up with surveillance imaging may be appropriate. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39668/abstract/1\">",
"      OCHSNER SF, CARRERA GM. Calcification of the gallbladder (\"porcelain gallbladder\"). Am J Roentgenol Radium Ther Nucl Med 1963; 89:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39668/abstract/2\">",
"      Berk RN, Armbuster TG, Saltzstein SL. Carcinoma in the porcelain gallbladder. Radiology 1973; 106:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39668/abstract/3\">",
"      Kane RA, Jacobs R, Katz J, Costello P. Porcelain gallbladder: ultrasound and CT appearance. Radiology 1984; 152:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39668/abstract/4\">",
"      CORNELL CM, CLARKE R. Vicarious calcification involving the gallbladder. Ann Surg 1959; 149:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39668/abstract/5\">",
"      Polk HC Jr. Carcinoma and the calcified gall bladder. Gastroenterology 1966; 50:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39668/abstract/6\">",
"      Stephen AE, Berger DL. Carcinoma in the porcelain gallbladder: a relationship revisited. Surgery 2001; 129:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39668/abstract/7\">",
"      Khan ZS, Livingston EH, Huerta S. Reassessing the need for prophylactic surgery in patients with porcelain gallbladder: case series and systematic review of the literature. Arch Surg 2011; 146:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39668/abstract/8\">",
"      Etala E. [Gallbladder cancer]. Prensa Med Argent 1967; 54:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39668/abstract/9\">",
"      Shimizu M, Miura J, Tanaka T, et al. Porcelain gallbladder: relation between its type by ultrasound and incidence of cancer. J Clin Gastroenterol 1989; 11:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39668/abstract/10\">",
"      Ashur H, Siegal B, Oland Y, Adam YG. Calcified ballbladder (porcelain gallbladder). Arch Surg 1978; 113:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39668/abstract/11\">",
"      Kim JH, Kim WH, Yoo BM, et al. Should we perform surgical management in all patients with suspected porcelain gallbladder? Hepatogastroenterology 2009; 56:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39668/abstract/12\">",
"      Brown KM, Geller DA. Porcelain gallbladder and risk of gallbladder cancer. Arch Surg 2011; 146:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39668/abstract/13\">",
"      Welch NT, Fitzgibbons RJ Jr, Hinder RA. Beware of the porcelain gallbladder during laparoscopic cholecystectomy. Surg Laparosc Endosc 1991; 1:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39668/abstract/14\">",
"      Tomioka T, Tajima Y, Inoue K, et al. Laparoscopic cholecystectomy is a safe procedure for the treatment of porcelain gallbladder. Endoscopy 1997; 29:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39668/abstract/15\">",
"      Kwon AH, Inui H, Matsui Y, et al. Laparoscopic cholecystectomy in patients with porcelain gallbladder based on the preoperative ultrasound findings. Hepatogastroenterology 2004; 51:950.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 643 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-FDE34C00CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39668=[""].join("\n");
var outline_f38_47_39668=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK OF MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Plain abdominal roentgenogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Computerized tomogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/643\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/643|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/0/35840\" title=\"diagnostic image 1\">",
"      Porcelain gallbladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/36/32321\" title=\"diagnostic image 2\">",
"      Porcelain gallbladder CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/2/10273\" title=\"diagnostic image 3\">",
"      Porcelain gallbladder US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/643|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/45/41685\" title=\"picture 1\">",
"      Porcelain gallbladder Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15082?source=related_link\">",
"      Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_47_39669="Prevention of herpes simplex virus type 1 infection in immunocompetent patients";
var content_f38_47_39669=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of herpes simplex virus type 1 infection in immunocompetent patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39669/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39669/contributors\">",
"     Robyn S Klein, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39669/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39669/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39669/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39669/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/47/39669/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus type 1 (HSV-1) may cause gingivostomatitis, which is characterized by vesiculoulcerative lesions of the oral mucosa. Reactivation of HSV-1 occurs in the trigeminal sensory ganglion and may lead to herpes labialis (eg, \"cold sores\"), which often occurs along the vermillion border of the lip.",
"   </p>",
"   <p>",
"    The prevention of HSV-1 infections will be reviewed here. The clinical manifestations and treatment of primary and episodic recurrent HSV infections are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment and prophylaxis of HSV-1 infections in the immunocompromised patient are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVENTIVE VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently no effective vaccine against HSV-1 infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In recurrent cutaneous HSV-1 infection, there is a sequential infiltrate of CD4+ and then CD8+ T lymphocytes into lesions. CD4 lymphocytes produce intralesional IFN-gamma and recognize the structural proteins of HSV (ie, glycoproteins D and B) when restimulated in vitro. Research on the immunodominant epitopes of these two glycoproteins may help inform future vaccine trials in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AVAILABLE ANTIVIRAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral agents for HSV infection include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    ; metabolites of these nucleoside derivatives interfere with the synthesis of viral DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/4\">",
"     4",
"    </a>",
"    ]. Of all the human herpesviruses, acyclovir has the greatest in vitro activity against HSV-1 and HSV-2. The triphosphate form of acyclovir inhibits viral DNA polymerase.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     Famciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    have greater oral bioavailability than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/5\">",
"     5",
"    </a>",
"    ] and are dosed less frequently, but are generally more expensive. The margin of safety and tolerability of all three medications is excellent since these medications are selectively converted to active compounds within virally infected cells. Acyclovir is the only medication of this group that can be dosed intravenously. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30003?source=see_link\">",
"     \"Valacyclovir: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6308?source=see_link\">",
"     \"Famciclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    and topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/23/12659?source=see_link\">",
"     penciclovir",
"    </a>",
"    have also been studied for recurrent herpes labialis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/4\">",
"     4",
"    </a>",
"    ]. Topical treatment with each of these agents requires frequent daily applications (acyclovir five times a day or penciclovir nine times a day). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dosing regimens and duration for prophylaxis of HSV-1 infections are not well established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS FOR RECURRENT HSV WITH IDENTIFIED TRIGGER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both iatrogenic and natural triggers can lead to predictable HSV-1 infections in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. Treatment trials have addressed a variety of strategies of managing these patients.",
"   </p>",
"   <p>",
"    Management of sporadic recurrent HSV-1 infection is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sunlight exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have well-documented triggers (eg, intense sunlight exposure) leading to HSV-1 reactivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Various treatment strategies have been evaluated to prevent these recurrences, including sunscreen and topical and oral antiviral therapies. No studies have directly compared any of these strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Sunscreen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A placebo-controlled crossover trial of 38 patients showed that after ultraviolet (UV) light exposure, herpes labialis developed in 27 patients (71 percent) treated with placebo with a mean time to HSV recurrence of 2.9 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/11\">",
"     11",
"    </a>",
"    ]. In contrast, when sunscreen was applied before UV light exposure, no lesions developed, although 1 of the 35 patients shed virus at the exposure site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placebo-controlled trials of topical antiviral creams have shown conflicting results as to whether treatment des the risk of recurrence in patients with light-induced herpes labialis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Oral antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data on the benefit of antiviral therapy in patients with a well-recognized trigger for HSV reactivation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial was performed among 237 skiers with a history of recurrent labial herpes triggered by sun exposure to determine if",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      could lead to a lower frequency of HSV reactivation or faster lesion resolution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/6\">",
"       6",
"      </a>",
"      ]. Oral acyclovir (800 mg twice daily) was initiated 12 to 24 hours before sun exposure and continued for three to seven days. Patients in the treatment arm did not have any clinical benefit compared with those in the placebo arm.",
"     </li>",
"     <li>",
"      In another trial, 147 skiers with a history of sun-induced recurrences of HSV-1 were treated prophylactically with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      or matching placebo and were observed during their ski holidays [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/14\">",
"       14",
"      </a>",
"      ]. This study demonstrated a clinical benefit of acyclovir prophylaxis; 5 (7 percent) of 75 acyclovir-treated subjects developed lesions compared with 19 (26 percent) of 72 persons in the placebo group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Surgical procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with a history of HSV infection, herpes labialis occurs in approximately 50 to 70 percent of patients undergoing trigeminal nerve root decompression or facial dermabrasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/15-17\">",
"     15-17",
"    </a>",
"    ] and in 10 to 15 percent of patients undergoing dental extractions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. There are conflicting data as to whether dental surgery leads to an increase in asymptomatic viral shedding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a controlled trial of 30 patients,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      initiated the night before trigeminal surgery at 400 mg twice daily for five days led to a high degree of protection against HSV reactivation; 1 of 14 patients had an episode of HSV infection compared with 12 of 16 among the placebo recipients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/22\">",
"       22",
"      </a>",
"      ]. Of note, no selection for prior herpes labialis infections or presence of antibodies to HSV was required for participation in the trial. At day three after surgery, HSV-positive cultures were demonstrated in 12 of 16 placebo recipients versus 3 of 14 patients on the treatment arm.",
"     </li>",
"     <li>",
"      No episodes of HSV reactivation were seen among 84 patients undergoing dermabrasion who initiated prophylaxis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (500 mg BID for 14 postoperative days) over the 21-day period of observation; however, the study did not include a placebo arm for comparison [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest use of antiviral prophylaxis for patients who are undergoing trigeminal nerve root decompression or facial dermabrasion. The optimal regimen and duration of treatment are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HSV-ASSOCIATED ERYTHEMA MULTIFORME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary and recurrent HSV infections have also been associated rarely with the development of erythema multiforme (EM). HSV antigen has been demonstrated in skin lesion biopsy samples from such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal management of such patients is unknown. In one study of patients with childhood HSV-associated erythema multiforme, treatment with topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    or oral acyclovir (25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) was not effective in decreasing the duration of the EM lesions, which lasted a mean of 11 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/5\">",
"     5",
"    </a>",
"    ]. These data suggest that a better approach to these patients may be the use of chronic suppressive therapy, which means daily administration of an antiviral agent, such as acyclovir.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREVENTION OF HSV IN HEALTH CARE WORKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health care providers should use gloves during physical examination of a patient with active HSV lesions to prevent personal acquisition of HSV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PREVENTION OF SEXUAL TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HSV-1 has a particular tropism for mucosal and cutaneous skin sites, it can also cause genital ulcer disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Transmission of HSV-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with oral HSV infection (primary or recurrent) should be educated that they can transmit HSV-1 through oral sex to their uninfected partner resulting in genital ulcers. This issue may be particularly important if their HSV-negative partner is pregnant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=see_link\">",
"     \"Genital herpes simplex virus infection and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Condom use",
"    </span>",
"    &nbsp;&mdash;&nbsp;No studies have specifically assessed risk factors for sexual transmission of HSV-1, although seropositivity for both HSV-1 and HSV-2 infections has been associated with an increased risk of HSV-2 transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/18\">",
"     18",
"    </a>",
"    ]. A large, pooled prospective analysis of partner transmission of HSV-2 among 528 discordant couples was performed to assess the role of condom use in prevention of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/18\">",
"     18",
"    </a>",
"    ]. The results demonstrated moderate protection against HSV-2 transmission in women when condoms were used during more than 25 percent of sex acts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39669/abstract/18\">",
"     18",
"    </a>",
"    ]. However, whether condom use is effective against sexual transmission of HSV-1 specifically has not been evaluated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    is effective against transmission of genital HSV-2 infection in discordant couples, but its role in the prevention of sexual transmission of HSV-1 infection has not been studied. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no available vaccine for the prevention of HSV-1 infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Preventive vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the use of prophylactic sunscreen in patients with a history of light-induced reactivation of HSV infection (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prophylaxis for recurrent HSV with identified trigger'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with a history of HSV infection, herpes labialis occurs in approximately 50 to 70 percent of patients undergoing trigeminal nerve root decompression or facial dermabrasion and in 10 to 15 percent of patients undergoing dental extractions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prophylaxis for recurrent HSV with identified trigger'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest use of antiviral prophylaxis for patients who are undergoing trigeminal nerve root decompression (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We also suggest antiviral prophylaxis for patients with a history of recurrent herpes labialis who are undergoing facial dermabrasion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prophylaxis for recurrent HSV with identified trigger'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with oral HSV infection (primary or recurrent) should be educated that they can transmit HSV-1 through oral sex to their uninfected partner resulting in genital ulcers. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prevention of sexual transmission'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/1\">",
"      Whitley RJ, Roizman B. Herpes simplex viruses: is a vaccine tenable? J Clin Invest 2002; 110:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/2\">",
"      Kim M, Taylor J, Sidney J, et al. Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects. J Immunol 2008; 181:6604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/3\">",
"      Chentoufi AA, Zhang X, Lamberth K, et al. HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J Immunol 2008; 180:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/4\">",
"      Kesson AM. Use of aciclovir in herpes simplex virus infections. J Paediatr Child Health 1998; 34:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/5\">",
"      Weston WL, Morelli JG. Herpes simplex virus-associated erythema multiforme in prepubertal children. Arch Pediatr Adolesc Med 1997; 151:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/6\">",
"      Raborn GW, Martel AY, Grace MG, McGaw WT. Oral acyclovir in prevention of herpes labialis. A randomized, double-blind, multi-centered clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/7\">",
"      Spruance SL, Rowe NH, Raborn GW, et al. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, dose-ranging, placebo-controlled, multicenter trial. J Infect Dis 1999; 179:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/8\">",
"      Spruance SL, Freeman DJ, Stewart JC, et al. The natural history of ultraviolet radiation-induced herpes simplex labialis and response to therapy with peroral and topical formulations of acyclovir. J Infect Dis 1991; 163:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/9\">",
"      Gilbert SC. Suppressive therapy versus episodic therapy with oral valacyclovir for recurrent herpes labialis: efficacy and tolerability in an open-label, crossover study. J Drugs Dermatol 2007; 6:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/10\">",
"      Mills J, Hauer L, Gottlieb A, et al. Recurrent herpes labialis in skiers. Clinical observations and effect of sunscreen. Am J Sports Med 1987; 15:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/11\">",
"      Rooney JF, Bryson Y, Mannix ML, et al. Prevention of ultraviolet-light-induced herpes labialis by sunscreen. Lancet 1991; 338:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/12\">",
"      Evans TG, Bernstein DI, Raborn GW, et al. Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis. Antimicrob Agents Chemother 2002; 46:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/13\">",
"      Bernstein DI, Schleupner CJ, Evans TG, et al. Effect of foscarnet cream on experimental UV radiation-induced herpes labialis. Antimicrob Agents Chemother 1997; 41:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/14\">",
"      Spruance SL, Hamill ML, Hoge WS, et al. Acyclovir prevents reactivation of herpes simplex labialis in skiers. JAMA 1988; 260:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/15\">",
"      Wall SH, Ramey SJ, Wall F. Famciclovir as antiviral prophylaxis in laser resurfacing procedures. Plast Reconstr Surg 1999; 104:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/16\">",
"      Alster TS, Nanni CA. Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. Dermatol Surg 1999; 25:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/17\">",
"      Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med 1992; 327:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/18\">",
"      Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med 2009; 169:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/19\">",
"      Openshaw H, Bennett HE. Recurrence of herpes simplex virus after dental extraction. J Infect Dis 1982; 146:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/20\">",
"      Hyland PL, Coulter WA, Abu-Ruman I, et al. Asymptomatic shedding of HSV-1 in patients undergoing oral surgical procedures and attending for noninvasive treatment. Oral Dis 2007; 13:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/21\">",
"      Marques-Silva L, Castro WH, Gomez EL, et al. The impact of dental surgery on HSV-1 reactivation in the oral mucosa of seropositive patients. J Oral Maxillofac Surg 2007; 65:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/22\">",
"      Sch&auml;delin J, Schilt HU, Rohner M. Preventive therapy of herpes labialis associated with trigeminal surgery. Am J Med 1988; 85:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39669/abstract/23\">",
"      Gilbert S, McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: A randomized clinical trial of dosing regimens. Dermatol Surg 2000; 26:50.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8287 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39669=[""].join("\n");
var outline_f38_47_39669=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVENTIVE VACCINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AVAILABLE ANTIVIRAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROPHYLAXIS FOR RECURRENT HSV WITH IDENTIFIED TRIGGER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sunlight exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Sunscreen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Oral antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Surgical procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HSV-ASSOCIATED ERYTHEMA MULTIFORME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREVENTION OF HSV IN HEALTH CARE WORKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PREVENTION OF SEXUAL TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Transmission of HSV-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Condom use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6308?source=related_link\">",
"      Famciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=related_link\">",
"      Genital herpes simplex virus infection and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30003?source=related_link\">",
"      Valacyclovir: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_47_39670="Chronic asthma in children younger than 12 years: Quick-relief agents";
var content_f38_47_39670=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic asthma in children younger than 12 years: Quick-relief agents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39670/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39670/contributors\">",
"     Gregory Sawicki, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39670/contributors\">",
"     Kenan Haver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39670/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39670/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39670/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39670/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39670/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/47/39670/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-acting bronchodilating agents (SABA) remain a cornerstone of the treatment of chronic childhood asthma. The use of these drugs generally provides rapid relief of coughing, wheezing, chest tightness, and shortness of breath.",
"   </p>",
"   <p>",
"    Medications used for the quick-relief of asthma symptoms in children younger than 12 years of age will be reviewed here. The recommendations below are based upon National Asthma Education and Prevention Program (NAEPP) Expert panel guidelines published in 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of children with asthma, an overview of asthma management, long-term control agents, and the management of acute asthma exacerbations in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33034?source=see_link\">",
"     \"Acute asthma exacerbations in children: Outpatient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11642?source=see_link\">",
"     \"Acute asthma exacerbations in children: Inpatient management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quick-relief medications are taken to relieve bronchoconstriction in acute asthma exacerbation. Quick-relief agents include short-acting beta-2 agonists (SABA), anticholinergic bronchodilators (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/12/35008?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide), and short-term systemic glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SHORT-ACTING BETA-2 AGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend SABA (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    [salbutamol],",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/52/18245?source=see_link\">",
"     levalbuterol",
"    </a>",
"    ) for the quick relief of asthma symptoms (eg, wheeze, cough, shortness of breath, chest tightness) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/1\">",
"     1",
"    </a>",
"    ]. SABA relaxes airway smooth muscle, leading to a prompt increase in airflow. Repetitive or continuous administration of SABA is the most effective means of reversing airflow obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/2-7\">",
"     2-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SABA should not be prescribed on a regular schedule because of concerns about a possible relationship between the frequent use of these agents and deteriorating asthma control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. The rapid relief provided by SABA may invite misuse and overuse, such that other medical intervention may be delayed beyond a safe point in an asthma exacerbation. Frequent use of SABA is an indication of poor asthma control and should prompt increased use of controller therapy (",
"    <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"     figure 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78322 graphicRef64986 \" href=\"mobipreview.htm?29/50/30510\">",
"     table 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/19/16698?source=see_link\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Racemic albuterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, a racemic mixture of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    is the primary SABA used for quick relief in both the outpatient and inpatient settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Levalbuterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/52/18245?source=see_link\">",
"     Levalbuterol",
"    </a>",
"    , the R-enantiomer, is the active isomer of racemic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    that confers the bronchodilator effects. Levalbuterol is approved in the United States for treatment of bronchospasm in children &ge;4 years via HFA MDI and &ge;6 years via solution for nebulization.",
"   </p>",
"   <p>",
"    Several studies have demonstrated favorable efficacy and safety profiles for",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/52/18245?source=see_link\">",
"     levalbuterol",
"    </a>",
"    compared to racemic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    , including one in which the hospitalization rate was lower among children who received levalbuterol in the emergency department (36 versus 45 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. However, other studies have failed to find a benefit of levalbuterol with respect to respiratory parameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2007 NAEPP guidelines suggest that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/52/18245?source=see_link\">",
"     levalbuterol",
"    </a>",
"    provides clinically comparable bronchodilation and systemic side effects as racemic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/1\">",
"     1",
"    </a>",
"    ]. They include it as a quick-relief medication for children aged 5 to 11 years (",
"    <a class=\"graphic graphic_table graphicRef59229 \" href=\"mobipreview.htm?14/10/14509\">",
"     table 2",
"    </a>",
"    ). In our opinion, available data do not support widespread use of levalbuterol instead of racemic albuterol as a quick-relief medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other SABA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other SABA used in the management of chronic childhood asthma include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/9/1172?source=see_link\">",
"     metaproterenol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/1/26?source=see_link\">",
"     pirbuterol",
"    </a>",
"    , fenoterol (not available in the United States), and bitolterol (not available in the United States). Not all of these agents are approved for use in children younger than 12 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Route of delivery",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Inhaled",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled SABA (",
"    <a class=\"graphic graphic_table graphicRef59229 \" href=\"mobipreview.htm?14/10/14509\">",
"     table 2",
"    </a>",
"    ) have the advantages of smaller doses, fewer side effects, and more rapid onset of action than oral agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/16\">",
"     16",
"    </a>",
"    ]. They provide symptomatic relief and thus reduce the morbidity of asthma and the amount of family disruption it engenders.",
"   </p>",
"   <p>",
"    Inhaled SABA are typically administered through a metered dose inhaler with attached spacer device along with infant- or child-sized mask or by nebulization as appropriate for size and developmental age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/17\">",
"     17",
"    </a>",
"    ]. A number of factors influence the amount of drug actually deposited in the lower airways with either of these methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31014?source=see_link&amp;anchor=H4#H4\">",
"     \"Delivery of inhaled medication in children\", section on 'Factors affecting drug deposition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30376?source=see_link\">",
"     \"Use of medication nebulizers in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36760?source=see_link\">",
"     \"The use of inhaler devices in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important for patients who use inhalers to know how to tell when the inhaler is near empty to ensure that they will have access to bronchodilator therapy during an acute exacerbation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36760?source=see_link&amp;anchor=H5#H5\">",
"     \"The use of inhaler devices in children\", section on 'Determining when an MDI is empty'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Oral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral beta agonists (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/9/1172?source=see_link\">",
"     metaproterenol",
"    </a>",
"    ) may be beneficial in preschool children with mild, episodic asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/19\">",
"     19",
"    </a>",
"    ]. However, they have frequent systemic effects, such as tachycardia, tremor, and behavioral and sleep disturbance. As a general rule, inhaled SABA are preferred if they can be administered because they have a shorter onset of action and fewer side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     IPRATROPIUM BROMIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/12/35008?source=see_link\">",
"     Ipratropium",
"    </a>",
"    bromide is an anticholinergic drug that provides bronchodilation through smooth muscle relaxation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20870?source=see_link&amp;anchor=H6#H6\">",
"     \"Anticholinergic agents in the management of acute exacerbations of asthma\", section on 'Use in children'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/12/35008?source=see_link\">",
"     Ipratropium",
"    </a>",
"    bromide as an adjunct to SABA in the emergency department management of acute asthma exacerbations in children. In randomized trials, systematic review, and meta-analysis, multiple doses of inhaled ipratropium combined with SABA have been shown to reduce hospital admissions and improve lung function in children with severe asthma exacerbations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33034?source=see_link&amp;anchor=H26#H26\">",
"     \"Acute asthma exacerbations in children: Outpatient management\", section on 'Ipratropium bromide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/12/35008?source=see_link\">",
"     Ipratropium",
"    </a>",
"    bromide also may be used as an alternative quick-relief agent for patients who do not tolerate SABA, but it has not been adequately studied for this indication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/12/35008?source=see_link\">",
"     Ipratropium",
"    </a>",
"    can be administered MDI and spacer or via nebulizer. The MDI formulation should not be administered to patients with allergy to peanut or soy because it contains soya lecithin, which may precipitate an allergic reaction.",
"   </p>",
"   <p>",
"    Potential adverse effects of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/12/35008?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide include drying of mouth, blurred vision, urinary retention tachycardia, and central nervous system effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SYSTEMIC GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend a short course of oral glucocorticoids in addition to short-acting beta-2 agonists for children who present to the clinic or emergency department with moderate or severe asthma exacerbation. In addition, the NAEPP guidelines recommend the initiation of oral glucocorticoids in the home setting in certain circumstances (eg, if initiation of oral glucocorticoids is part of the asthma action plan",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    after contacting the health care provider) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/1\">",
"     1",
"    </a>",
"    ]. In systematic review and meta-analysis, early institution of oral glucocorticoids reduces the duration of exacerbation and can prevent hospitalization and relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33034?source=see_link&amp;anchor=H24#H24\">",
"     \"Acute asthma exacerbations in children: Outpatient management\", section on 'Systemic glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INHALED GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 NAEPP expert panel no longer recommends doubling the dose of inhaled glucocorticoids (also called inhaled corticosteroids, ICS) in patients already receiving inhaled glucocorticoids for quick relief during an acute asthma exacerbation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/1\">",
"     1",
"    </a>",
"    ]. This strategy has not proven effective in reducing the severity or preventing the progression of exacerbations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/1,28-32\">",
"     1,28-32",
"    </a>",
"    ]. However, higher doses of inhaled glucocorticoids (more than two times the usual dose) may be an alternative for mild to moderate exacerbations in patients who have serious adverse effects with systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39670/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37354?source=see_link&amp;anchor=H13#H13\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\", section on 'Intermittent preventive use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/58/17315?source=see_link\">",
"       \"Patient information: Asthma in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/4/33858?source=see_link\">",
"       \"Patient information: How to use your child&rsquo;s metered dose inhaler (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/60/18374?source=see_link\">",
"       \"Patient information: Asthma treatment in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Quick-relief medications are taken to relieve bronchoconstriction in acute asthma exacerbations. Quick-relief agents include short-acting beta-2 agonists (SABA), anticholinergic bronchodilators (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/12/35008?source=see_link\">",
"       ipratropium",
"      </a>",
"      bromide), and short-term systemic glucocorticoids. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend short-acting beta-2 agonists for the quick relief of asthma symptoms (eg, wheeze, cough, shortness of breath, chest tightness) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Short-acting beta-2 agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/12/35008?source=see_link\">",
"       ipratropium",
"      </a>",
"      bromide as an adjunct to SABA in the emergency department management of acute asthma exacerbations in children (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Ipratropium bromide'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33034?source=see_link&amp;anchor=H26#H26\">",
"       \"Acute asthma exacerbations in children: Outpatient management\", section on 'Ipratropium bromide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend a short course of oral glucocorticoids in addition to short-acting beta-2 agonists for children who present to the clinic or emergency department with a moderate or severe asthma exacerbation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33034?source=see_link&amp;anchor=H26#H26\">",
"       \"Acute asthma exacerbations in children: Outpatient management\", section on 'Ipratropium bromide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest NOT increasing the dose of inhaled glucocorticoids to treat an acute asthma exacerbation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Inhaled glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Asthma Education and Prevention Program: Expert Panel Report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD. National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 01, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/2\">",
"      Camargo CA Jr, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev 2003; :CD001115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/3\">",
"      Karpel JP, Aldrich TK, Prezant DJ, et al. Emergency treatment of acute asthma with albuterol metered-dose inhaler plus holding chamber: how often should treatments be administered? Chest 1997; 112:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/4\">",
"      Rudnitsky GS, Eberlein RS, Schoffstall JM, et al. Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department. Ann Emerg Med 1993; 22:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/5\">",
"      Lin RY, Sauter D, Newman T, et al. Continuous versus intermittent albuterol nebulization in the treatment of acute asthma. Ann Emerg Med 1993; 22:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/6\">",
"      Ben-Zvi Z, Lam C, Hoffman J, et al. An evaluation of the initial treatment of acute asthma. Pediatrics 1982; 70:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/7\">",
"      Rossing TH, Fanta CH, Goldstein DH, et al. Emergency therapy of asthma: comparison of the acute effects of parenteral and inhaled sympathomimetics and infused aminophylline. Am Rev Respir Dis 1980; 122:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/8\">",
"      Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/9\">",
"      Gawchik SM, Saccar CL, Noonan M, et al. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999; 103:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/10\">",
"      Handley DA, Tinkelman D, Noonan M, et al. Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma 2000; 37:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/11\">",
"      Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998; 102:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/12\">",
"      Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003; 143:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/13\">",
"      L&ouml;tvall J, Palmqvist M, Arvidsson P, et al. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001; 108:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/14\">",
"      Hardasmalani MD, DeBari V, Bithoney WG, Gold N. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 2005; 21:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/15\">",
"      Qureshi F, Zaritsky A, Welch C, et al. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005; 46:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/16\">",
"      Larson S, Svedmyr N. Bronchodilating effects and side effects of beta-2-adrenostimulants by different routes of administration. Am Rev Respir Dis 1972; 116:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/17\">",
"      Conner WT, Dolovich MB, Frame RA, Newhouse MT. Reliable salbutamol administration in 6- to 36-month-old children by means of a metered dose inhaler and Aerochamber with mask. Pediatr Pulmonol 1989; 6:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/18\">",
"      Whelan AM, Hahn NW. Optimizing drug delivery from metered-dose inhalers. DICP 1991; 25:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/19\">",
"      Nussbaum E, Galant SP. Bronchodilator effects of oral metaproterenol sulfate in preschool children with asthma. J Pediatr 1987; 110:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/20\">",
"      Jones CA, Madison JM, Tom-Moy M, Brown JK. Muscarinic cholinergic inhibition of adenylate cyclase in airway smooth muscle. Am J Physiol 1987; 253:C97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/21\">",
"      Zorc JJ, Pusic MV, Ogborn CJ, et al. Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics 1999; 103:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/22\">",
"      Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 1998; 339:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/23\">",
"      Schuh S, Johnson DW, Callahan S, et al. Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. J Pediatr 1995; 126:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/24\">",
"      Plotnick LH, Ducharme FM. Combined inhaled anticholinergic agents and beta-2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev 2000; :CD000060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/25\">",
"      Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax 2005; 60:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/26\">",
"      Rachelefsky G. Treating exacerbations of asthma in children: the role of systemic corticosteroids. Pediatrics 2003; 112:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/27\">",
"      Rowe BH, Spooner C, Ducharme FM, et al. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 2001; :CD002178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/28\">",
"      FitzGerald JM, Becker A, Sears MR, et al. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004; 59:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/29\">",
"      Garrett J, Williams S, Wong C, Holdaway D. Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid. Arch Dis Child 1998; 79:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/30\">",
"      Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; 363:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/31\">",
"      Rice-McDonald G, Bowler S, Staines G, Mitchell C. Doubling daily inhaled corticosteroid dose is ineffective in mild to moderately severe attacks of asthma in adults. Intern Med J 2005; 35:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/32\">",
"      Schuh S, Dick PT, Stephens D, et al. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma. Pediatrics 2006; 118:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39670/abstract/33\">",
"      Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group. Chest 2000; 117:440.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5743 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-197.136.42.3-3C9D172F08-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39670=[""].join("\n");
var outline_f38_47_39670=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SHORT-ACTING BETA-2 AGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Racemic albuterol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Levalbuterol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other SABA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Route of delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Inhaled",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Oral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IPRATROPIUM BROMIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SYSTEMIC GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INHALED GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5743\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5743|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/40/37506\" title=\"figure 1A\">",
"      Stepwise asthma Rx 0 to 4 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/41/1684\" title=\"figure 1B\">",
"      Stepwise asthma Rx 5 to 11 yrs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5743|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/62/12269\" title=\"table 1A\">",
"      Adjusting Rx 0 to 4 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/13/26845\" title=\"table 1B\">",
"      Adjusting Rx 5 to 11 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/10/14509\" title=\"table 2\">",
"      Doses asthma reliever meds kids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11642?source=related_link\">",
"      Acute asthma exacerbations in children: Inpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33034?source=related_link\">",
"      Acute asthma exacerbations in children: Outpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20870?source=related_link\">",
"      Anticholinergic agents in the management of acute exacerbations of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/19/16698?source=related_link\">",
"      Beta agonists in asthma: Controversy regarding chronic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37354?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Controller medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26010?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31014?source=related_link\">",
"      Delivery of inhaled medication in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/58/17315?source=related_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/60/18374?source=related_link\">",
"      Patient information: Asthma treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/4/33858?source=related_link\">",
"      Patient information: How to use your child&rsquo;s metered dose inhaler (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36760?source=related_link\">",
"      The use of inhaler devices in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30376?source=related_link\">",
"      Use of medication nebulizers in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_47_39671="Airway remodeling";
var content_f38_47_39671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Airway remodeling in asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ET-1: endothelin-1; FGF-2: fibroblast growth factor; IGF-1: insulin-like growth factor-1; IL: interleukin; LTC4: leukotriene C4; MMP-9: matrix metalloproteinase-9; PDGF: platelet-derived growth factor; TGF&beta;: transforming growth factor &beta;; TNF&alpha;: tumor necrosis factor &alpha;; TIMP-1: tissue inhibitor of metalloproteinase-1; EGF: epidermal growth factor; GM-CSF: granulocyte macrophage colony stimulating factor; VEGF: vascular endothelial growth factor.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39671=[""].join("\n");
var outline_f38_47_39671=null;
var title_f38_47_39672="Implantable cardioverter-defibrillators: Patient follow-up";
var content_f38_47_39672=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Implantable cardioverter-defibrillators: Patient follow-up",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39672/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39672/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39672/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39672/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39672/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39672/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/47/39672/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac arrhythmic death (SCD) is a common problem that usually results from ventricular fibrillation (VF) that is sometimes preceded by monomorphic or polymorphic ventricular tachycardia (VT). The implantable cardioverter-defibrillator (ICD) has become the dominant therapeutic modality for the treatment of these patients, as a number of randomized trials have found that ICDs reduce SCD mortality in survivors of",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    and also when used for primary prevention in patients at high risk of SCD.",
"   </p>",
"   <p>",
"    Among survivors of",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    who receive an ICD, the main role of antiarrhythmic drugs is as adjunctive therapy (eg, to reduce frequent ICD shocks). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to monitoring, recurrent syncope, and pregnancy after implantation of an ICD and possible permanent cessation of ICD therapy will be reviewed here. The clinical trials supporting the efficacy of the ICD and the general principles and complications associated with ICD therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30599?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FOLLOW-UP OF THE PATIENT WITH AN ICD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an ICD are easily followed in the clinic for device evaluation and retrieval of stored information (device interrogation); remote follow-up is now available as well, with remote follow-up systems replacing some office follow-up visits. Such assessments are made both on a routine basis and when device discharge occurs.",
"   </p>",
"   <p>",
"    Patients with an ICD should be evaluated every three months. Follow-up can occur in the office, or remotely using vendor specific equipment, to interrogate and \"upload\" data to a secure web site via the patient's telephone line or a cellular transmitter. Remote follow-up systems permit device interrogation and retrieval of diagnostic data, but not threshold testing or reprogramming. Remote monitoring appears to have similar safety and efficacy as standard office monitoring. In a study of 433 patients with an ICD who were randomized to remote home monitoring (with daily data transmittal and one scheduled office visit per year) or standard office monitoring every six months and were then followed for an average of two years, the rate of major adverse events was similar in both groups (39 versus 42 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Device interrogation and a detailed review of device function should be performed with each visit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/2\">",
"     2",
"    </a>",
"    ]. Monitoring for device infection and evidence of local device complications should also be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link&amp;anchor=H6#H6\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link&amp;anchor=H12#H12\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Pulse generator complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Device interrogation includes the evaluation of several aspects of device function by telemetry:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The programmed detection criteria and programmed therapy for VT and VF are reviewed in detail.",
"     </li>",
"     <li>",
"      Pacing and sensing thresholds are obtained as well as pacing and shocking lead impedances and signal amplitudes and morphologies.",
"     </li>",
"     <li>",
"      Recorded episodes of arrhythmia detection and device activation, including pacing and shocks, are evaluated. Although older devices merely counted the number of shocks a patient received, current devices include the date and time of each episode and store the electrograms from the event.",
"     </li>",
"     <li>",
"      In systems containing an atrial lead, diagnostic information regarding atrial arrhythmias is reviewed. Many ICD patients have subclinical atrial fibrillation (AF), and clinical trials suggest a higher thromboembolic risk. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=see_link\">",
"       \"Risk of embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Battery status is assessed, indicating when the pulse generator must be electively replaced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Testing of defibrillation function has been performed on a routine basis in the past, although it has been suggested that such testing may be best reserved for specific clinical settings. Extraction and replacement of the defibrillator lead may be necessary for a variety of reasons, although many defibrillator leads will last for the life of the patient and never need replacement. Replacement of the pulse generator (known interchangeably as the device, the generator, the battery, or the ICD) is done electively before battery life is exceeded. Current devices should last six to eight years or longer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=see_link&amp;anchor=H8#H8\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Elements of the ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Defibrillator discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defibrillator discharge is an anticipated aspect of long-term follow-up in patients with an ICD. In an analysis from the AVID trial, the largest randomized trial of ICD therapy for the secondary prevention of SCD, an appropriate shock was delivered in 53 percent of patients by two years post-implantation. This is an important issue for driving. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/20/30024?source=see_link&amp;anchor=H4#H4\">",
"     \"Driving restrictions in patients with an implantable cardioverter-defibrillator\", section on 'Overall incidence of ventricular arrhythmias and ICD shocks'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not all episodes of defibrillator discharge require immediate medical evaluation. Patients with a first (or other early) shock may be seen on an urgent or elective basis to ascertain that the device is functioning properly and to provide patient reassurance. Remote monitoring systems also permit rapid, convenient assessment of diagnostic data. Discharges that are accompanied by changes in cognition (syncope, seizure, or loss of consciousness) or that are associated with cardiac arrest should be regarded as medical emergencies requiring immediate transport to a hospital emergency department.",
"   </p>",
"   <p>",
"    Patients who receive multiple shocks or clusters of shocks generally require emergent evaluation and hospital admission to determine the cause. Such recurrent discharges may be either appropriate (due to recurrent VT) or inappropriate (due to atrial fibrillation or supraventricular tachycardia with a rapid rate, or to device malfunction).",
"   </p>",
"   <p>",
"    If frequent discharges are due to recurrent VT, additional therapy (such as an antiarrhythmic drug or catheter ablation) may be required. In AVID, 18 percent of patients assigned to an ICD required the subsequent addition of an antiarrhythmic drug, primarily for frequent shocks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several clinical trials have suggested that patients who receive appropriate ICD therapy have a higher mortality than patients who do not. In the SCD-HeFT trial, both appropriate and inappropriate ICD therapy were associated with a higher mortality during follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/3\">",
"     3",
"    </a>",
"    ]. The delivery of therapy by an ICD, therefore, should prompt clinicians to re-evaluate the patient's overall clinical status and therapeutic plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DEFIBRILLATION FUNCTION TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defibrillation function is usually measured by the defibrillation threshold (DFT). The DFT is the amount of energy (in joules) that is necessary to defibrillate the heart. Defibrillation function is often tested at the time of device insertion, although the necessity for this evaluation has been questioned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Method of testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the step-down approach to DFT testing, VF is induced, either with high frequency current delivered through the lead or a low energy shock on the T wave. The device should then appropriately sense and identify the arrhythmia and deliver a shock. If the shock defibrillates the heart, the testing is repeated after five minutes using a lower energy (step-down technique). This sequence is repeated until defibrillation does not occur. The patient is then rescued with a higher energy shock (up to 40 joules) delivered through the lead system. A back-up external defibrillator is always immediately available if transvenous shocks fail. The lowest successful energy is considered the DFT.",
"   </p>",
"   <p>",
"    The DFT is usually &le;15 joules and often less than 10 joules with biphasic shocks and improved lead systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The defibrillating shock in early ICDs had a monophasic waveform. Subsequent studies using biphasic waveforms (an initial positive phase followed by a phase of opposite polarity) have demonstrated the clinical superiority of this approach (",
"    <a class=\"graphic graphic_figure graphicRef51842 \" href=\"mobipreview.htm?23/36/24140\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/9\">",
"     9",
"    </a>",
"    ]. All current devices feature biphasic waveforms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/24/8585?source=see_link&amp;anchor=H5#H5\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\", section on 'Defibrillatory waveforms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to variations in conditions (eg, ischemia, heart failure, autonomic and circadian fluctuations) and the probabilistic nature of defibrillation, a shock delivered at the energy level of the DFT will not always defibrillate the heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, an ICD must be able to deliver a shock at a higher energy than a patient's DFT to provide a margin of safety. A safety margin of at least 10 joules is usually recommended.",
"   </p>",
"   <p>",
"    The DFT and the safety margin define the minimum level of energy required from the ICD system for a given patient. This is important for two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standard, contemporary ICDs can deliver 35 to 41 joules; some older devices delivered only 30 joules. In a patient with a high DFT, the maximum energy available from a standard ICD may not be 10 joules greater than the DFT. In order to achieve this safety margin, it is necessary to use a device that provides higher energy shocks",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      to implant additional leads (eg, defibrillator coils that are added to improve the shocking vector either in the azygos vein, coronary sinus, or tunneled subcutaneously posteriorly). The additional ICD leads usually result in a lower DFT, due to the \"sandwiching\" of more LV myocardium between the shocking electrodes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a patient with a low DFT, the energy level of the initial shock can be programmed below the ICD maximum, as long as it is at or above the desired safety margin. The advantage of a lower energy initial shock is that therapy is delivered several seconds earlier, because the time required to charge the device is less.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some reports have suggested that a lower margin of safety (eg, 5 to 7 joules), is as effective as 10 joules, with a success rate for initial shocks of 94 to 96 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/8,13\">",
"     8,13",
"    </a>",
"    ]. However, these data are from a series of shocks delivered in a controlled setting under anesthesia. As noted above, the energy requirement and defibrillation efficacy may be different during spontaneous ventricular arrhythmias. As a result, we continue to recommend a safety margin of 10 joules or more in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     DFT testing at the time of ICD implantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defibrillation threshold (DFT) testing has typically been performed at the time of device implantation, although the necessity for this evaluation with the current generation of devices has been questioned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/4,14,15\">",
"     4,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early ICD systems frequently required lead system adjustment at the time of implantation in order to achieve an adequate safety margin. As technology improved, thresholds were substantially reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/16\">",
"     16",
"    </a>",
"    ]. As a result, it is now unusual for the standard triad defibrillation system (two shock coils and an active can) to require modification at the time of implantation (",
"    <a class=\"graphic graphic_figure graphicRef74224 \" href=\"mobipreview.htm?23/23/23925\">",
"     figure 2",
"    </a>",
"    ). Two studies illustrate the impact of DFT testing at the time of ICD implantation with the current generation of devices:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective analysis of 975 consecutive patients undergoing ICD implantation (809 [83 percent] of whom had DFT testing at the time of implantation) at a single center from 1998 to 2009, only 11 patients (1.4 percent) had lead-related issues requiring intervention identified at the time of DFT testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial of heart failure patients receiving an ICD with or without cardiac resynchronization therapy, 145 patients were randomly assigned to ICD implantation with (70 patients) or without (75 patients) DFT testing at the time of implantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/15\">",
"       15",
"      </a>",
"      ]. All patients who underwent DFT testing were successfully defibrillated, only 4 percent required any system modifications, and there were no significant outcome differences between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the apparently low incidence of problems identified at the time of DFT testing pre-discharge, many electrophysiologists feel that omitting DFT testing might compromise the safety of those patients with high DFTs who would benefit from a higher energy device",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    additional leads, and DFT testing remains part of the standard implantation procedure in most hospitals. However, outside of clinical trials, few implanters carry out formal top-down DFT testing at each implant. More common is verification of the safety margin, where 1 or 2 inductions of ventricular fibrillation are performed to verify that there is a safety margin of at least 10 joules (eg, test with 20 to 30 joules with a 40 joule device). Additionally, operators may be able to reduce the energy required for defibrillation and shorten the charging time, thereby reducing energy output and battery consumption while potentially reducing the duration of myocardial and cerebral ischemia experienced by the patient during any future sustained arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     DFT testing as part of routine follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, many centers retested defibrillation function prior to discharge and routinely during follow-up. However, the induction and termination of a ventricular tachyarrhythmia has potential complications, is unpleasant for the patient, and adds additional cost. In addition, one study of 50 patients receiving a pectoral implant with a transvenous lead system found no significant increase in DFT during the first two years after implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for routine ICD testing was reviewed in a series that retrospectively analyzed 1007 defibrillation tests in 556 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/18\">",
"     18",
"    </a>",
"    ]. During routine testing, only 0.4 percent of systems failed to defibrillate the patient; in all but one case, abnormalities with the system had been observed prior to testing (eg, changes in lead pacing or sensing function, or substantial changes in lead impedance). The practice of routine DFT testing during follow-up has largely been abandoned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     DFT testing after the initiation of antiarrhythmic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One predictor of a higher DFT is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. Amiodarone, and particularly its major metabolite desethylamiodarone, increase the DFT in a dose-dependent fashion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. The NASPE (HRS) guidelines for amiodarone therapy recommend that, whenever amiodarone is initiated in a patient with an ICD, the ICD should be reevaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link&amp;anchor=H13#H13\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Antiarrhythmic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, whether repeat DFT testing is actually necessary after the initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or other antiarrhythmic drugs is not clear. In the report on the efficacy of routine ICD testing discussed above, 71 patients had an ICD test due to the initiation or dose-adjustment of an antiarrhythmic drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/18\">",
"     18",
"    </a>",
"    ]. The ICD failed to defibrillate two patients (2.8 percent).",
"   </p>",
"   <p>",
"    The role of ICD testing after the initiation of antiarrhythmic therapy was more directly assessed in a substudy of the OPTIC trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/24\">",
"     24",
"    </a>",
"    ]. The OPTIC trial compared the efficacy of three drug regimens as adjunctive therapy in patients with an ICD; beta blockers,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    plus a beta blocker, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    . In the substudy, 94 patients from this trial underwent serial ICD testing to determine the impact of each of these drug regimens on DFTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/24\">",
"     24",
"    </a>",
"    ]. At a mean follow-up of 60 days after drug initiation, the mean DFT decreased from baseline in the patients assigned to beta blockers or sotalol (8.8 to 7.1 and 8.1 to 7.2 joules, respectively). Among patients taking amiodarone, there was a nonsignificant increase in the mean DFT from 8.5 to 9.8 joules. The authors suggested that routine ICD testing after the initiation of antiarrhythmic therapy is not necessary. However, the number of patients in each arm of this study is only 29 to 35, and the small mean increase does not preclude the possibility that there may be a larger increase in some patients. Thus, the necessity for ICD testing after the initiation of antiarrhythmic drugs, primarily amiodarone, remains uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link&amp;anchor=H12#H12\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Adjunctive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another effect of antiarrhythmic drug therapy is to slow the rate of VT when it recurs. Thus, it is common practice to lower the VT detection cut-off when initiating antiarrhythmic drug therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the above data, we suggest that DFT should be performed in the following settings (",
"    <a class=\"graphic graphic_table graphicRef79427 \" href=\"mobipreview.htm?30/22/31083\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At the time of ICD implantation to confirm appropriate device function and an adequate safety margin (ie, the difference between the DFT and the maximum energy available from the ICD). The safety margin is generally preferred to be &ge;10 joules.",
"     </li>",
"     <li>",
"      In follow-up, in patients in whom ICD dysfunction is suspected or those who have a significant change in clinical status.",
"     </li>",
"     <li>",
"      DFT testing should be considered after an antiarrhythmic drug, in particular",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , has been initiated or the dose has been increased. This is most important when amiodarone has been initiated in a patient in whom the defibrillation safety margin (ie, maximum device output minus defibrillation threshold) at implant was relatively small. The value of repeat testing in this setting is probably more important in patients with a high baseline DFT, and possibly in patients with more severe or progressive heart disease (eg, severe left ventricular dysfunction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      advanced heart failure).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Due to the limited and inconsistent nature of the data available in this area, many clinicians choose alternative strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RECURRENT SYNCOPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the ICD reduces SCD and total mortality, there is still a risk of recurrent syncope, which has implications for driving restrictions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/20/30024?source=see_link\">",
"     \"Driving restrictions in patients with an implantable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This issue was addressed in a review of 421 patients with an ICD who were followed for a mean of 26 months; 54 percent had recurrent VT or VF, and 15 percent had syncope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/26\">",
"     26",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased risk of syncope was associated with a baseline left ventricular ejection fraction (LVEF) &le;40 percent, induction of fast VT during electrophysiologic testing (cycle length &lt;300 ms), and chronic atrial fibrillation.",
"     </li>",
"     <li>",
"      If the LVEF was &gt;40 percent and fast VT was not induced, 96 and 92 percent of patients remained free of syncope at one and three years.",
"     </li>",
"     <li>",
"      Among patients with VT recurrence, syncope and a fast VT rate were the strongest predictors for future syncope.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recurrent syncope may not be associated with an increase in mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/27\">",
"     27",
"    </a>",
"    ]. In some cases, syncope may be the result of proarrhythmic effects of the ICD itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/27\">",
"     27",
"    </a>",
"    ]. In patients with recurrent syncope, this possibility should be explored, as device programming may reduce the likelihood of further events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link&amp;anchor=H19#H19\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Proarrhythmia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young women with life-threatening ventricular tachyarrhythmias often receive an ICD, allowing many of them to reach their reproductive years and become pregnant. A retrospective study evaluated 44 women with an ICD (mean age 26 years) who became pregnant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/28\">",
"     28",
"    </a>",
"    ]. Eleven patients had one or more shocks during the pregnancy, and the average number of shocks was 0.66 for the entire study group. There were no adverse effects on the fetus as a result of the shock; 39 babies were born healthy, two were small for gestational age, one had transient hypoglycemia, and there was one stillborn. One woman had a therapeutic abortion unrelated to the ICD.",
"   </p>",
"   <p>",
"    Thus, the presence of an ICD is not a contraindication for pregnancy, and pregnancy does not increase the risk of an ICD complication or result in a high number of ICD shocks. Among women of child-bearing age with an ICD, the risks associated with pregnancy are based upon her general condition and the severity of underlying heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/7/29818?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29097?source=see_link\">",
"     \"Acquired heart disease and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DISCONTINUATION OF ICD THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discontinuation of ICD therapy is a complicated issue, which usually arises in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A belief that the device is no longer necessary, usually because it has never delivered a therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      there has been an improvement in the patient's cardiac condition.",
"     </li>",
"     <li>",
"      The goals of care have changed (eg, the patient",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the health care proxy have decided that the patient should not be resuscitated).",
"     </li>",
"     <li>",
"      A device complication, usually infection, necessitates removal of the device",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      leads.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patient preference",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients (or their health care proxies), may request that an ICD be removed or disabled either because of a perceived lack of need for the device or because of a change in the goals of care.",
"   </p>",
"   <p>",
"    There is little experience or data to define which patients, if any, who had an appropriate indication for ICD implantation could safely have an ICD disabled or removed due to a reduction in SCD risk. Data from trials of ICD therapy for primary prevention have shown that many patients first experience SCD several years after a myocardial infarction. Thus, a prolonged period without an arrhythmic event should not be interpreted as evidence that the patient is no longer at risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When discontinuation of ICD therapy is requested because of a change in the goals of care, the role of the clinician is to explain fully the implications of the decision. Some issues that may be important include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with a terminal illness and a poor short-term prognosis, the pain from an ICD shock can be contrary to a primary goal of maintaining the patient's comfort. When a patient with an ICD has a new diagnosis of a terminal illness, the option of disabling ICD therapies should be included in broader discussions of end-of-life care. Many patients will choose to disable ICD therapies, resulting in fewer shocks in the final days of a terminal illness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/29\">",
"       29",
"      </a>",
"      ]. A consensus document discusses the management of patients with pacemakers and ICDs nearing end-of-life or desiring withdrawal of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among more active and healthy patients, some individuals request that they not be resuscitated due to a fear of recovery to an incapacitated state requiring long-term mechanical support. Because an ICD treats potentially lethal arrhythmias very rapidly, patients usually recover to their baseline condition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Device complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is occasionally necessary to remove an ICD due to a complication, most commonly structural failure or infection. When a device is removed, the patient is no longer protected from SCD, and a decision must be made about if and when to place a new ICD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44345?source=see_link\">",
"     \"Infections involving cardiac implantable electronic devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Removal of the ICD itself (known interchangeably as the device, the generator, or the battery), is relatively straightforward and is usually done in the electrophysiology laboratory. In contrast, lead extraction typically requires specialized equipment and, due to the risk of vascular injury, it is sometimes performed in an operating room.",
"   </p>",
"   <p>",
"    In a series of 161 lead extractions at the Cleveland Clinic between 1991 and 1999, 75 were performed for infection and 55 for conductor failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/31\">",
"     31",
"    </a>",
"    ]. Other causes included insulation failure, oversensing or undersensing, pacemaker-ICD interaction, lead upgrade, and permanent device removal. Complete extraction was achieved in 158 patients, with extraction of most of the lead in two; one patient required surgical removal. One patient died and one suffered a respiratory arrest; minor complications occurred in seven patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link&amp;anchor=H8#H8\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Lead complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/12/30921?source=see_link\">",
"     \"Cardiac implantable electronic device lead removal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When device removal is necessary, the patient can be monitored in the short-term in the hospital and treated with external defibrillation if a ventricular arrhythmia develops. In the medium-term, a wearable cardioverter defibrillator (WCD) can be prescribed. However, in the long-term, decisions regarding the implantation of a new device are complicated and unique to each individual. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36088?source=see_link\">",
"     \"Wearable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Implantation of a second ICD and new leads is more challenging than an initial implant, but can usually be accomplished. Issues to be considered include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of recurrent infection &mdash; Implantation of a new device is usually not considered until the initial infection has been fully treated. At that point, risk factors for recurrent systemic infections that could involve the new device (eg, immunosuppression, hemodialysis) may outweigh the potential benefit of a new ICD.",
"     </li>",
"     <li>",
"      Anatomy and vascular access &mdash; It is often not possible to place the device in the same site as the original implant. Lack of adequate vascular access may necessitate an epicardial device (which requires a thoracotomy). Thus, the risks associated with a new device are usually greater than those of an initial implant and may be prohibitive.",
"     </li>",
"     <li>",
"      The patient's estimated risk of SCD &mdash; Among patients at a high risk of SCD (eg, those with a history of multiple arrhythmic events and ICD therapies), the risk-benefit assessment may still favor device reimplantation despite the challenges.",
"     </li>",
"     <li>",
"      The availability of alternative therapies &mdash; Alternatives to an ICD include a wearable external defibrillator, residence in a long-term monitored setting, or equipping the patient's home with an external defibrillator.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known about the outcome after ICD removal. A review of eight reports included a total of 151 patients who had an ICD explanted for a variety of reasons, 50 due to discontinuation of aggressive therapy in the setting of a terminal illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39672/abstract/32\">",
"     32",
"    </a>",
"    ]. Among the remaining patients, over follow-up periods of 1 to 30 months, 27 percent died and 7 patients had new ICDs implanted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the above observations, we suggest the following approach when the discontinuation of ICD therapy is considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a patient or the appropriate proxy requests discontinuation due to a change in the goals of care, device therapies can be disabled without removing the device. If pacemaker support is necessary and remains consistent with the goals of care, the ICD can be programmed to function as a pacemaker, or the ICD can be replaced with a pacemaker.",
"     </li>",
"     <li>",
"      When a device-related complication necessitates removal of the ICD",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      leads, consideration must be given to both short- and long-term protection from SCD. In the short-term, patients should be maintained on continuous monitoring until a definitive long-term plan is established. In the long-term, most patients remain at an elevated risk of SCD and, if possible, a new ICD should be implanted when it is considered safe.",
"     </li>",
"     <li>",
"      Patients who request ICD removal due to a perceived reduction in SCD risk should be advised that there is no evidence to suggest that any patient who had an ICD implanted for appropriate indications will ever have such a reduction in risk that an ICD is no longer necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/39/34419?source=see_link\">",
"       \"Patient information: Sudden cardiac arrest (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=see_link\">",
"       \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    The following summary and recommendations apply to the follow-up of patients with an ICD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with an ICD should have the device interrogated every three to six months to assess lead function, programmed parameters and arrhythmia history. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Follow-up of the patient with an ICD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients who have had a single device discharge with immediate return to baseline clinical status and no associated symptoms (eg, chest pain, shortness of breath, or lightheadedness), should have the device interrogated, usually within one to two days (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A single successful shock that is not accompanied by any associated symptoms does not require emergent evaluation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Defibrillator discharge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients who experience multiple device discharges over a short period of time",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      have significant associated symptoms following a single device discharge should go to an emergency department for immediate evaluation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link&amp;anchor=H20#H20\">",
"       \"Implantable cardioverter-defibrillators: Complications\", section on 'Electrical storm'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The delivery of therapy by an ICD should prompt clinicians to re-evaluate the patient's overall clinical status and therapeutic plan.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is some disagreement as to the need for DFT testing in various settings. We suggest DFT testing in the following situations (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At the time of device implantation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'DFT testing at the time of ICD implantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When there is a suspected deterioration in ICD function. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'DFT testing as part of routine follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In selected patients, after the initial loading or an increased dose of an antiarrhythmic drug, especially",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , particularly when the defibrillation safety margin at implant was relatively small. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'DFT testing after the initiation of antiarrhythmic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The discontinuation of ICD therapy is appropriate in limited settings, including a change in the goals of care or a device complication. This is usually accomplished by device reprogramming in the former case and explantation in the latter. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Discontinuation of ICD therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who had an appropriate indication for ICD implantation appear to have an increased risk of SCD indefinitely, even if their overall condition improves or several years pass without an arrhythmic event. For this reason, ICD therapy should not be discontinued based upon a belief that the device is no longer necessary. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Patient preference'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/1\">",
"      Gu&eacute;don-Moreau L, Lacroix D, Sadoul N, et al. A randomized study of remote follow-up of implantable cardioverter defibrillators: safety and efficacy report of the ECOST trial. Eur Heart J 2013; 34:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/2\">",
"      Winters SL, Packer DL, Marchlinski FE, et al. Consensus statement on indications, guidelines for use, and recommendations for follow-up of implantable cardioverter defibrillators. North American Society of Electrophysiology and Pacing. Pacing Clin Electrophysiol 2001; 24:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/3\">",
"      Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008; 359:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/4\">",
"      Strickberger SA, Klein GJ. Is defibrillation testing required for defibrillator implantation? J Am Coll Cardiol 2004; 44:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/5\">",
"      Rashba EJ, Olsovsky MR, Shorofsky SR, et al. Temporal decline in defibrillation thresholds with an active pectoral lead system. J Am Coll Cardiol 2001; 38:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/6\">",
"      Newman D, Barr A, Greene M, et al. A population-based method for the estimation of defibrillation energy requirements in humans. Assessment of time-dependent effects with a transvenous defibrillation system. Circulation 1997; 96:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/7\">",
"      Hodgson DM, Olsovsky MR, Shorofsky SR, et al. Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing Clin Electrophysiol 2002; 25:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/8\">",
"      Carlsson J, Schulte B, Erdogan A, et al. Prospective randomized comparison of two defibrillation safety margins in unipolar, active pectoral defibrillator therapy. Pacing Clin Electrophysiol 2003; 26:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/9\">",
"      Schneider T, Martens PR, Paschen H, et al. Multicenter, randomized, controlled trial of 150-J biphasic shocks compared with 200- to 360-J monophasic shocks in the resuscitation of out-of-hospital cardiac arrest victims. Optimized Response to Cardiac Arrest (ORCA) Investigators. Circulation 2000; 102:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/10\">",
"      Venditti FJ Jr, John RM, Hull M, et al. Circadian variation in defibrillation energy requirements. Circulation 1996; 94:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/11\">",
"      Butter C, Meisel E, Tebbenjohanns J, et al. Transvenous biventricular defibrillation halves energy requirements in patients. Circulation 2001; 104:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/12\">",
"      Kall JG, Kopp D, Lonchyna V, et al. Implantation of a subcutaneous lead array in combination with a transvenous defibrillation electrode via a single infraclavicular incision. Pacing Clin Electrophysiol 1995; 18:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/13\">",
"      Strickberger SA, Daoud EG, Davidson T, et al. Probability of successful defibrillation at multiples of the defibrillation energy requirement in patients with an implantable defibrillator. Circulation 1997; 96:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/14\">",
"      Day JD, Doshi RN, Belott P, et al. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations). Circulation 2007; 115:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/15\">",
"      Healey JS, Gula LJ, Birnie DH, et al. A randomized-controlled pilot study comparing ICD implantation with and without intraoperative defibrillation testing in patients with heart failure and severe left ventricular dysfunction: a substudy of the RAFT trial. J Cardiovasc Electrophysiol 2012; 23:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/16\">",
"      Kopp DE, Blakeman BP, Kall JG, et al. Predictors of defibrillation energy requirements with nonepicardial lead systems. Pacing Clin Electrophysiol 1995; 18:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/17\">",
"      Guenther M, Rauwolf T, Br&uuml;ggemann B, et al. Pre-hospital discharge testing after implantable cardioverter defibrillator implantation: a measure of safety or out of date? A retrospective analysis of 975 patients. Europace 2012; 14:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/18\">",
"      Brunn J, B&ouml;cker D, Weber M, et al. Is there a need for routine testing of ICD defibrillation capacity? Results from more than 1000 studies. Eur Heart J 2000; 21:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/19\">",
"      Khalighi K, Daly B, Leino EV, et al. Clinical predictors of transvenous defibrillation energy requirements. Am J Cardiol 1997; 79:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/20\">",
"      Zhou L, Chen BP, Kluger J, et al. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol 1998; 31:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/21\">",
"      Pelosi F Jr, Oral H, Kim MH, et al. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. J Cardiovasc Electrophysiol 2000; 11:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/22\">",
"      Nielsen TD, Hamdan MH, Kowal RC, et al. Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation. Am J Cardiol 2001; 88:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/23\">",
"      Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000; 160:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/24\">",
"      Hohnloser SH, Dorian P, Roberts R, et al. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation 2006; 114:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/25\">",
"      Glikson M, Friedman P. Routine arrhythmia inductions for ICD follow-up: are they obsolete? Pacing Clin Electrophysiol 2001; 24:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/26\">",
"      B&auml;nsch D, Brunn J, Castrucci M, et al. Syncope in patients with an implantable cardioverter-defibrillator: incidence, prediction and implications for driving restrictions. J Am Coll Cardiol 1998; 31:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/27\">",
"      Olatidoye AG, Verroneau J, Kluger J. Mechanisms of syncope in implantable cardioverter-defibrillator recipients who receive device therapies. Am J Cardiol 1998; 82:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/28\">",
"      Natale A, Davidson T, Geiger MJ, Newby K. Implantable cardioverter-defibrillators and pregnancy: a safe combination? Circulation 1997; 96:2808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/29\">",
"      Lewis WR, Luebke DL, Johnson NJ, et al. Withdrawing implantable defibrillator shock therapy in terminally ill patients. Am J Med 2006; 119:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/30\">",
"      Lampert R, Hayes DL, Annas GJ, et al. HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm 2010; 7:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/31\">",
"      Saad EB, Saliba WI, Schweikert RA, et al. Nonthoracotomy implantable defibrillator lead extraction: results and comparison with extraction of pacemaker leads. Pacing Clin Electrophysiol 2003; 26:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39672/abstract/32\">",
"      Geist M, Newman D, Greene M, et al. Permanent explantation of implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2000; 23:2024.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1015 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39672=[""].join("\n");
var outline_f38_47_39672=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FOLLOW-UP OF THE PATIENT WITH AN ICD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Defibrillator discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DEFIBRILLATION FUNCTION TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Method of testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DFT testing at the time of ICD implantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DFT testing as part of routine follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DFT testing after the initiation of antiarrhythmic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RECURRENT SYNCOPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DISCONTINUATION OF ICD THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patient preference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Device complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1015\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1015|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/36/24140\" title=\"figure 1\">",
"      Defibrillation waveforms in ICDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/23/23925\" title=\"figure 2\">",
"      Transvenous ICD lead systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1015|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/22/31083\" title=\"table 1\">",
"      Clinical circumstances for ICD evaluation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29097?source=related_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/12/30921?source=related_link\">",
"      Cardiac implantable electronic device lead removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/20/30024?source=related_link\">",
"      Driving restrictions in patients with an implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30599?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44345?source=related_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/39/34419?source=related_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/24/8585?source=related_link\">",
"      Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36088?source=related_link\">",
"      Wearable cardioverter-defibrillator",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_47_39673="Clinical manifestations and evaluation of pulmonary tuberculosis";
var content_f38_47_39673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and evaluation of pulmonary tuberculosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39673/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39673/contributors\">",
"     Anton Pozniak, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39673/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39673/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39673/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39673/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/47/39673/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lungs are the major site for Mycobacterium tuberculosis infection. Clinical manifestations of tuberculosis (TB) include primary TB, reactivation TB, laryngeal TB, endobronchial TB, lower lung field TB infection, and tuberculoma. Pulmonary complications of TB can include hemoptysis, pneumothorax, bronchiectasis, extensive pulmonary destruction, malignancy, and chronic pulmonary aspergillosis.",
"   </p>",
"   <p>",
"    The clinical manifestations and evaluation of pulmonary TB will be reviewed here. The clinical manifestations of pulmonary TB in children and HIV-infected patients are discussed separately, as are the epidemiology, pathogenesis, laboratory diagnosis, and treatment of pulmonary TB. Extrapulmonary and miliary TB are also discussed separately. (See related topics.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1528649\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Primary tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary tuberculosis (TB) was considered to be mainly a disease of childhood until the introduction of effective chemotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    in the 1950s. Many studies since that time have shown an increased frequency in the acquisition of TB in adolescents and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of primary TB was well described in a prospective study of 517 new tuberculin converters living on the Faroe Islands off the coast of Norway from 1932 to 1946 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/3\">",
"     3",
"    </a>",
"    ]. The study included 331 adults and 186 children; all were followed for more than five years. The clinical manifestations of primary TB varied substantially in this population, and symptoms and signs referable to the lungs were present in approximately one-third of patients. Fever was the most common symptom, occurring in 70 percent of 232 patients in whom fever was not a condition for enrollment in the study. The fever onset was generally gradual and low grade but could be as high as 39&ordm;C and lasted for an average of 14 to 21 days. Fever resolved in 98 percent of patients by 10 weeks.",
"   </p>",
"   <p>",
"    Fever was not usually accompanied by other symptoms, although approximately 25 percent of patients developed pleuritic or retrosternal pain. One-half of patients with pleuritic chest pain had evidence of a pleural effusion. Retrosternal and dull interscapular pain were ascribed to enlarged bronchial lymph nodes and sometimes worsened with swallowing. Rarer symptoms included fatigue, cough, arthralgias, and pharyngitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12856?source=see_link\">",
"     \"Tuberculous pleural effusions in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/47/22261?source=see_link\">",
"     \"Tuberculous pleural effusions in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Radiographic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In primary pulmonary TB, the chest radiograph is often normal. The most common chest radiograph abnormality in one series was hilar adenopathy, occurring in 65 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/3\">",
"     3",
"    </a>",
"    ]. Hilar changes could be seen as early as one week after skin test conversion and within two months in all cases. These radiographic findings resolved slowly, often over a period of more than one year.",
"   </p>",
"   <p>",
"    Approximately one-third of the 517 converters developed pleural effusions, typically within the first three to four months after infection, but occasionally as late as one year. Pulmonary infiltrates were documented in 27 percent of patients. Perihilar and right sided infiltrates were the most common, and ipsilateral hilar enlargement was the rule. While contralateral hilar changes sometimes were present, only 2 percent of patients had bilateral infiltrates. Lower and upper lobe infiltrates were observed in 33 and 13 percent of adults, respectively; 43 percent of adults with infiltrates also had effusions. Most infiltrates resolved over months to years. However, in 20 patients (15 percent of cases), the infiltrates progressed within the first year after skin test conversion, so-called progressive primary TB. The majority of these patients had progression of disease at the original site, and four developed cavitation.",
"   </p>",
"   <p>",
"    Other studies which provide insight into the clinical manifestations of TB have focused retrospectively upon patients with culture-proven TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In one series from Canada, 188 patients were assessed, all of whom were culture positive and had abnormal chest radiographs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/5\">",
"     5",
"    </a>",
"    ]. Thirty patients (18 percent) were classified clinically as having primary TB. The most common finding was hilar lymphadenopathy, present in 67 percent. Right middle lobe collapse may complicate the adenopathy but usually resolves with therapy.",
"   </p>",
"   <p>",
"    Several factors probably favor involvement of the right middle lobe:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It is more densely surrounded by lymph nodes.",
"     </li>",
"     <li>",
"      It has a relatively longer length and smaller internal caliber.",
"     </li>",
"     <li>",
"      It has a sharper branching angle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this retrospective series, pleural effusions were present in 33 percent and were the sole abnormality in 23 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/5\">",
"     5",
"    </a>",
"    ]. Pulmonary infiltrates were present in 63 percent of patients, and 85 percent of infiltrates were in the mid- to lower lung fields. Two patients had cavitation and two others evidence of endobronchial spread.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146930397\">",
"    <span class=\"h3\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;After primary infection, 90 percent of individuals with intact immunity control further replication of the bacilli, which may then enter a latent phase. The remaining 10 percent of individuals develop a TB pneumonia with expansion of infiltrates at the site of the initial seeding or near the hilum, and may have hilar lymphadenopathy or present with disease at more distant sites, commonly with cervical lymph nodes, meningitis, pericarditis, or miliary dissemination. Progression to local disease or dissemination occurs more frequently in those with poor immune responses, such as HIV, chronic kidney failure, poorly controlled diabetes mellitus, and older adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22378?source=see_link&amp;anchor=H13826069#H13826069\">",
"     \"Microbiology and pathogenesis of tuberculosis\", section on 'Natural history of infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reactivation tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple terms have been used to describe this stage of TB: chronic TB, postprimary disease, recrudescent TB, endogenous reinfection, and adult type progressive TB. Reactivation TB represents 90 percent of adult cases among HIV-negative individuals, and results from reactivation of a previously dormant focus seeded at the time of the primary infection. The apical posterior segments of the lung are frequently involved (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54832 \" href=\"mobipreview.htm?11/9/11409\">",
"     image 1",
"    </a>",
"    ). The original site of spread may have been previously visible as a small scar called a Simon focus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactivation TB may remain undiagnosed and potentially infectious for two to three years or longer, with development of symptoms only late in the course of the disease. The symptoms of reactivation TB have been described retrospectively, mainly in case series of hospitalized patients in single institutions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. In these series, symptoms typically began insidiously and were present for weeks or months before the diagnosis was made. One-half to two-thirds of patients developed cough, weight loss, and fatigue. Fever and night sweats or night sweats alone were present in approximately one-half. Chest pain and dyspnea each were reported in approximately one-third of patients, and hemoptysis in approximately one-quarter. Many patients had vague or nonspecific symptoms; almost one-third of patients had pulmonary TB diagnosed after an admission for unrelated complaints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fever is usually low grade at onset but becomes marked with progression of disease. It is classically diurnal, with an afebrile period early in the morning and a gradually rising temperature throughout the day, reaching a peak in the late afternoon or evening. Fever subsides during sleep but night sweats may occur. Fever and night sweats are more common among patients with advanced pulmonary TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cough may be absent or mild initially and may be nonproductive or productive of only scant sputum. Initially, it may be present only in the morning, when accumulated secretions during sleep are expectorated. As the disease progresses, cough becomes more continuous throughout the day and productive of yellow or yellow-green and occasionally blood-streaked sputum, which is rarely foul-smelling. Symptomatic individuals are more likely to have smear-positive sputum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/11\">",
"     11",
"    </a>",
"    ]. Frank hemoptysis, due to caseous sloughing or endobronchial erosion, typically occurs later in the disease and is rarely massive. Nocturnal coughing is associated with advanced disease, often with cavitation.",
"   </p>",
"   <p>",
"    Dyspnea can occur in the setting of extensive parenchymal involvement, pleural effusions, or a pneumothorax. Pleuritic chest pain is not common but, when present, signifies inflammation abutting or invading the pleura, with or without an effusion. Rarely this can progress to frank empyema. In the absence of treatment, patients may present with painful ulcers of the mouth, tongue, larynx, or GI tract due to chronic expectoration and swallowing of highly infectious secretions; these findings are rare in the setting of antituberculous therapy.",
"   </p>",
"   <p>",
"    Anorexia, wasting (consumption), and malaise are common features of advanced disease and may be the only presenting features in some patients.",
"   </p>",
"   <p>",
"    Ambulatory patients with active TB may have milder and less specific symptoms than hospitalized patients (",
"    <a class=\"graphic graphic_table graphicRef86232 \" href=\"mobipreview.htm?25/30/26093\">",
"     table 1",
"    </a>",
"    ). In a study including 313 TB cases identified among ambulatory patients, cough &gt;2 weeks was observed among 52 percent of patients with pulmonary disease; fever &gt;2 weeks was observed among 29 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, clinical symptoms were observed less frequently among patients of Asian ethnicity than other patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Presentation in older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;In nonendemic countries, the incidence of pulmonary TB is two to three times higher among older adults, especially those in old age homes, and the risk of death is higher compared with younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comparative studies have suggested some differences in manifestations of pulmonary TB between elderly and younger patients. A meta-analysis including 12 studies noted no significant difference between patients &gt;60 years and patients &lt;60 years with respect to time to diagnosis, prevalence of cough, sputum production, weight loss, or",
"    <span class=\"nowrap\">",
"     fatigue/malaise",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/15\">",
"     15",
"    </a>",
"    ]. Findings observed less commonly among the elderly included fever, sweats, hemoptysis, cavitary disease, and a positive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    , and they were likely to present with the nonspecific symptoms of dyspnea and fatigue. Findings observed more frequently among the elderly included hypoalbuminemia, leukopenia, and underlying disorders such as cardiovascular disease, chronic obstructive pulmonary disease (COPD), diabetes, malignancy, and gastrectomy. Cavitary disease is less common and multilobar and lower lobe involvement more common. Because of other comorbidities such as COPD, the diagnosis in older adults can be delayed or missed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical findings of pulmonary TB are not specific and usually are absent in mild or moderate disease. Dullness with decreased fremitus may indicate pleural thickening or effusion. Rales may be present throughout inspiration, or may be heard only after a short cough (post-tussive rales). When large areas of the lung are involved, signs of consolidation associated with open bronchi, such as whispered pectoriloquy or tubular breath sounds, may be heard. Distant hollow breath sounds over cavities are called amphoric, after the sound made by blowing across the mouth of jars used in antiquity (amphorae). Extrapulmonary signs include clubbing and findings localized to other sites of involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine hematology and biochemistry laboratory studies are frequently normal in the setting of pulmonary TB. The C-reactive protein (CRP) can be elevated in up to 85 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/18\">",
"     18",
"    </a>",
"    ]. Late in the disease, hematologic changes may include normocytic anemia, leukocytosis, or, more rarely, monocytosis. Hyponatremia may be associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/19\">",
"     19",
"    </a>",
"    ] or rarely with adrenal insufficiency. Hypoalbuminemia and hypergammaglobulinemia also can occur as late findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Radiographic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with reactivation TB have abnormalities on chest radiography, even in the absence of respiratory symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/7,20\">",
"     7,20",
"    </a>",
"    ]. Reactivation TB typically involves the apical-posterior segments of the upper lobes (80 to 90 percent of patients), followed in frequency by the superior segment of the lower lobes and the anterior segment of the upper lobes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54832 \" href=\"mobipreview.htm?11/9/11409\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62501 \" href=\"mobipreview.htm?40/40/41606\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/7,21-23\">",
"     7,21-23",
"    </a>",
"    ]. In multiple large series of TB among adults, 70 to 87 percent had upper lobe infiltrates typical of reactivation; 19 to 40 percent also had cavities, with visible air-fluid levels in as many as 20 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/7,21-23\">",
"     7,21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults without upper lobe infiltrates have &lsquo;atypical&rsquo; radiographic patterns (13 to 30 percent of cases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/4,24,25\">",
"     4,24,25",
"    </a>",
"    ]. These findings include hilar adenopathy (sometimes associated with right middle lobe collapse), infiltrates or cavities in the middle or lower lung zones, pleural effusions, and solitary nodules. These &lsquo;atypical&rsquo; findings are more common in the setting of primary TB and probably represent increasing incidence of primary TB rather than &lsquo;atypical&rsquo; forms of reactivation TB. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Primary tuberculosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Up to 5 percent of patients with active TB present with upper lobe fibrocalcific changes thought to be indicative of healed primary TB. However, such patients should be evaluated for active TB in the setting of pulmonary symptoms or absence of serial films documenting stability of the lesion.",
"   </p>",
"   <p>",
"    A normal chest radiograph is also possible even in active pulmonary TB. As an example, in one Canadian study of 518 patients with culture-proven pulmonary TB, 25 patients (5 percent) had normal chest x-rays; 23 of these patients had pulmonary symptoms at the time of the normal radiograph [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/26\">",
"     26",
"    </a>",
"    ]. In this series conducted over a 10-year period, normal chest x-rays represented less than 1 percent of the radiographs in 1988 to 1989, but increased to 10 percent from 1996 to 1997.",
"   </p>",
"   <p>",
"    Computed tomographic (CT) scanning is more sensitive than plain chest radiography for diagnosis, particularly for smaller lesions located in the apex of the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/27\">",
"     27",
"    </a>",
"    ]. CT scan may demonstrate a cavity or apicoposterior infiltrates, cavities, pleural effusions, fibrotic lesions causing distortion of lung parenchyma, elevation of fissures and hila, pleural adhesions, and formation of traction bronchiectasis. High-resolution (HR) CT is the imaging technique of choice to detect early bronchogenic spread. The most common findings consist of centrilobular 2- to 4-mm nodules or branching linear lesions representing intrabronchiolar and peribronchiolar caseation necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) has been used to show intrathoracic lymphadenopathy, pericardial thickening, and pericardial and pleural effusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no role for routine use of positron emission tomography (PET) for evaluation of TB. PET uptake of F-fluoro-2-deoxyglucose (FDG) does not differentiate infection from tumor, but the macrophages in active TB do not proliferate and do not need 11C-choline, resulting in low C-choline uptake; this in contrast to the macrophages in malignancy. Therefore, the combination of a high FDG and low 11C-choline uptake on PET may be useful, but not diagnostic of TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Endobronchial tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endobronchial TB is defined as tuberculous infection of the tracheobronchial tree. It may develop via direct extension to the bronchi from an adjacent parenchymal focus (usually a cavity), via spread of organisms to the bronchi via infected sputum, or via hematogenous spread. Lesions are more likely to be observed in the main and upper bronchi; in 5 percent of patients the lower trachea is involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the availability of antituberculous therapy, endobronchial TB was relatively common in the setting of primary infection and reactivation TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. In a 1943 study in a TB sanatorium in West Virginia, lesions in the tracheobronchial tree were observed in 15 percent of cases via rigid bronchoscopy and in 40 percent of cases at autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/32\">",
"     32",
"    </a>",
"    ]. Endobronchial disease was observed more frequently among patients with extensive pulmonary TB, particularly cavitary lesions. Upper lung parenchymal or cavitary disease with bronchogenic spread to the lower lung fields was commonly observed, presumably from pooled infected secretions.",
"   </p>",
"   <p>",
"    Since the availability of antituberculous therapy, endobronchial TB has been described in 10 to 40 percent of patients with active pulmonary TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Some degree of bronchial stenosis is observed in 90 percent of cases; early diagnosis and prompt treatment prior to development of fibrosis are important to reduce the likelihood of this complication. Endobronchial disease in patients with primary infection has also been associated with impingement of enlarged lymph nodes on the bronchi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Associated inflammation can lead to endobronchial ulceration or perforation. Other complications of endobronchial TB include obstruction, atelectasis (with or without secondary infection), bronchiectasis, and tracheal stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms may be acute in onset, and be confused with bacterial pneumonia, asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/43\">",
"     43",
"    </a>",
"    ], or foreign body aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/44\">",
"     44",
"    </a>",
"    ]. The clinical manifestations can also be subacute or chronic, resembling bronchogenic carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A barking cough has been described in approximately two-thirds of patients with endobronchial disease, often accompanied by sputum production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/40-42,45,46\">",
"     40-42,45,46",
"    </a>",
"    ]. Rarely patients develop so-called bronchorrhea, which is production of more than 500",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    of sputum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/47\">",
"     47",
"    </a>",
"    ]. In some cases, caseous material from endobronchial lesions or calcific material from extension of calcific nodes into the bronchi is expectorated, which is known as lithoptysis. Wheezing and hemoptysis may also be observed. Lymph node rupture can be associated with chest pain. The presence of dyspnea may signal obstruction or atelectasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diminished breath sounds, rhonchi, or wheezing may be heard. The wheeze is low-pitched, monophonic, constant, and is auscultated consistently over the same area on the chest wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Radiographic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal chest radiograph is observed in 10 to 20 percent of cases. The most common radiographic finding of endobronchial TB in adults is an upper lobe infiltrate and cavity with ipsilateral spread to the lower lobe and possibly to the superior segment of the contralateral lower lobe (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76337 \" href=\"mobipreview.htm?17/60/18373\">",
"     image 3",
"    </a>",
"    ). Patchy, small lower lobe infiltrates may progress to confluence or even cavitation. Extensive endobronchial TB can also be associated with bronchiectasis on CT scan.",
"   </p>",
"   <p>",
"    When endobronchial TB occurs in patients with primary disease, segmental atelectasis may be the only finding; atelectasis is more frequent in the right middle lobe and the anterior segment of the right upper lobe. Because endobronchial lesions can exist without extensive parenchymal abnormalities, normal chest radiographs may be observed in 10 to 20 percent of patients. In such cases, CT scanning may demonstrate endobronchial lesions or stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of endobronchial TB may be established by bronchoscopy, which may demonstrate erythematous, vascular,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ulcerated tissues. Granulation tissue may be bulky or polypoid. Hilar node rupture may be visible as a mass protruding into the bronchial lumen; with perforation of the node into the bronchus, caseous or calcific material may be seen extruding into the lumen. Bronchial stenosis also may be visible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/42,48\">",
"     42,48",
"    </a>",
"    ]. The likelihood of developing stenosis is increased in the setting of a distorted airway or a mass occluding the airway.",
"   </p>",
"   <p>",
"    Brushings of the lesions or lavage of the distal airways can increase the frequency of positive smears; the yield for cultures of this material is &gt;90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/31,36\">",
"     31,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9098?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\", section on 'Clinical specimens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment regimens for endobronchial disease are the same as for other forms of pulmonary TB. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of steroid therapy in the treatment of endobronchial disease is not certain. Steroids may improve acute inflammatory manifestations but have not been clearly shown to prevent long-term complications such as fibrosis and stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/41,49,50\">",
"     41,49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeated dilation, stents, and laser treatment have all been used for management of stenotic complications with varying success, dependent on case selection and operator skill. Resection may also be warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1528626\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146930772\">",
"    <span class=\"h3\">",
"     Laryngeal tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of antituberculous therapy, laryngeal TB was considered a terminal condition as it usually occurred during progression of pulmonary disease, developing soon before death. Since the availability of antituberculous therapy, laryngeal TB has become rare (&lt;1 percent of TB cases). It can also occur in the absence of pulmonary disease as an extrapulmonary manifestation. Symptoms include dysphonia, cough, dysphagia, odynophagia, stridor, and hemoptysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/54\">",
"     54",
"    </a>",
"    ]. The true vocal cords, epiglottis, and false vocal cords are the most common sites involved, and areas of hyperemia, nodules, ulcerations, or exophytic masses can be seen on laryngoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Lower lung field tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower lung field TB refers to disease involvement below the hila (including the perihilar regions) on a frontal chest x-ray [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/55\">",
"     55",
"    </a>",
"    ]. The incidence in adults is 2 to 9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/7,55\">",
"     7,55",
"    </a>",
"    ]. Consolidation in lower lung field TB tends to be more extensive and homogeneous than upper lobe TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Cavitation may occur, and large cavities have been described. Symptoms in lower lobe TB are generally either subacute in onset (mean of 12 weeks) or chronic (up to 6 months). Lower lobe TB is frequently misdiagnosed initially as viral or bacterial pneumonia, bronchiectasis, or carcinoma.",
"   </p>",
"   <p>",
"    Lower lobe involvement can be a manifestation of primary TB (with involvement of adjacent lymph nodes), reactivation TB (involving the superior segments of the lower lobes), or endobronchial TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/56,57,59\">",
"     56,57,59",
"    </a>",
"    ]. Endobronchial TB can affect lower lung fields in both primary infection (especially when adjacent lymph nodes are involved) and reactivation (spread from upper lobe disease can secondarily infect the lower lung fields).",
"   </p>",
"   <p>",
"    Older adult patients and those with HIV, diabetes, renal or hepatic disease, those receiving corticosteroids, and those with underlying silicosis appear at highest risk for lower lobe TB. However, many patients have no underlying medical illnesses. Studies in nursing homes suggest that lower lobe TB may be a manifestation of tuberculous infection in an older, tuberculin-negative population with significant underlying diseases or anergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/59\">",
"     59",
"    </a>",
"    ]. In some cases, the patients are suspected or known to have had previous TB but develop exogenous reinfection, perhaps due to a loss of demonstrable tissue hypersensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Tuberculoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rounded mass lesions can develop during primary infection or when a focus of reactivation TB becomes encapsulated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/58\">",
"     58",
"    </a>",
"    ]. Cavitation is rare. The differential diagnosis of pulmonary coin lesions is extensive, and the diagnosis of tuberculoma can be difficult since airway cultures are often negative. Fine needle aspiration or open lung biopsy may be necessary for diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44537?source=see_link\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF TUBERCULOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary complications of tuberculosis (TB) include hemoptysis, pneumothorax, bronchiectasis, extensive pulmonary destruction (including pulmonary gangrene), malignancy, and chronic pulmonary aspergillosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hemoptysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoptysis occurs most frequently in the setting of active tuberculosis, but may also occur after completion of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. Many patients with hemoptysis are acid-fast bacilli (AFB) smear positive and usually have cavitary disease. Bleeding usually is of small volume, appearing as blood-streaked sputum. Massive hemoptysis is a rare complication since the advent of chemotherapy. Prior to effective chemotherapy, massive hemoptysis accounted for approximately 5 percent of deaths from TB.",
"   </p>",
"   <p>",
"    Sources of massive hemoptysis due to TB include the pulmonary artery, bronchial arteries, intercostal arteries, and other vessels supplying the lung. \"Rasmussen's aneurysm\" refers to the formation of an aneurysm in the setting of cavitary infection which extends into the adventitia and media of bronchial arteries, resulting in inflammation and thinning of the vessel wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/63\">",
"     63",
"    </a>",
"    ]. This aneurysm subsequently ruptures into the cavity, producing massive hemoptysis. One autopsy series of 80 patients with TB noted the presence of Rasmussen's aneurysms in only 7 percent of patients with massive hemoptysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemoptysis after the completion of therapy for TB only occasionally represents TB recurrence. Other causes include residual bronchiectasis, an aspergilloma or other fungus ball invading or colonizing an old healed cavity, a ruptured broncholith that erodes through a bronchial artery, a carcinoma, or another infectious or inflammatory process.",
"   </p>",
"   <p>",
"    In some circumstances, conservative management is sufficient even for major or massive hemoptysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/65\">",
"     65",
"    </a>",
"    ], except in the cases of impending exsanguination, which require immediate surgical care. Initial care includes bed rest, postural management, volume replacement, cough suppression, and intravenous vasopressin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with significant hemoptysis should undergo rapid evaluation to define the source of bleeding and facilitate immediate intervention. Older studies suggest that after an episode of massive hemoptysis or repeated episodes of severe hemoptysis, surgical intervention improves survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. When medical management fails (25 to 50 percent of patients after 24 hours), options include surgical ligation of arteries, resection of a lung lobe, endobronchial tamponade, and bronchial artery embolization. Both ligation and embolization can be complex because of the frequent presence of multiple feeder arteries often connecting systemic with bronchial circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of antituberculous therapy, spontaneous pneumothorax was a frequent and dangerous complication of pulmonary TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/71\">",
"     71",
"    </a>",
"    ]. Since the availability of antituberculous therapy, spontaneous pneumothorax associated with TB has been reported in about 1 percent of hospitalized patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. A case series from Turkey reported pneumothorax in 1.5 percent of cases of pulmonary TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/74\">",
"     74",
"    </a>",
"    ]. In regions where TB is endemic, it may be the most common cause of spontaneous pneumothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pneumothorax appears to result from the rupture of a peripheral cavity or a subpleural caseous focus with liquefaction into the pleural space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Inflammation can lead to development of a bronchopleural fistula, which can persist or seal off spontaneously. The lung may reexpand if the bronchopleural fistula seals spontaneously, but more commonly tube drainage is required.",
"   </p>",
"   <p>",
"    Factors preventing successful tube drainage and expansion include extensive pulmonary parenchymal disease with large fistulas, a long interval between pneumothorax and chest tube insertion, and the development of an empyema due to TB",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bacterial superinfection. However, successful closure of even extensive air leaks has been reported after as much as six weeks of tube drainage accompanied by appropriate antituberculous chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Bronchiectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchiectasis may develop following primary or reactivation TB and can be associated with hemoptysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/77-82\">",
"     77-82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12458?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following primary TB infection, extrinsic compression of a bronchus by enlarged nodes may cause bronchial dilation distal to the obstruction. There may be no evidence of parenchymal TB.",
"   </p>",
"   <p>",
"    In the setting of reactivation TB, progressive destruction and fibrosis of lung parenchyma may lead to localized bronchial dilation. If endobronchial disease is present, bronchial stenosis may result in distal bronchiectasis. Bronchiectasis is more frequent in the common sites of reactivation TB (apical and posterior segments of the upper lobe), but may be found in other areas of the lung.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Extensive pulmonary destruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, TB can cause progressive, extensive destruction of areas of one or both lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. In primary TB, occasionally lymph node obstruction of the bronchi together with distal collapse, necrosis, and bacterial superinfection can produce parenchymal destruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/84\">",
"     84",
"    </a>",
"    ]. More commonly, destruction results from years of chronic reactivation TB, typically in the absence of effective chemotherapy. Symptoms include progressive dyspnea, hemoptysis, and weight loss.",
"   </p>",
"   <p>",
"    In one series of 18 patients with extensive destruction of one or both lungs, 8 died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/83\">",
"     83",
"    </a>",
"    ]. Causes of death were massive hemoptysis and respiratory failure, sometimes in the presence of active TB or superinfection. Radiographically patients had large cavities and fibrosis of remaining lung; in some cases, air-fluid levels at the base of the destroyed lung were observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary gangrene refers to acute pulmonary destruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/85\">",
"     85",
"    </a>",
"    ]. Patients with this form of TB progress rapidly from a homogeneous, extensive infiltrate to dense consolidation. Air-filled cysts develop and coalesce into cavities. Necrotic lung tissue attached to the wall of the cavity may be observed. Pulmonary gangrene may resemble an intracavitary clot, fungus ball, or Rasmussen's aneurysm. Pathology demonstrates arteritis and thrombosis of the vessels supplying the necrotic lung. Mortality usually is high; in one small series, 75 percent of patients died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/85\">",
"     85",
"    </a>",
"    ]. Resolution with effective therapy has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/86\">",
"     86",
"    </a>",
"    ],",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13013757\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study conducted by the National Cancer Institute found that pulmonary tuberculosis was associated with an increased risk of lung cancer, after adjustment for active smoking and socioeconomic status (odds ratio [OR] = 2.1, 95% CI: 1.4-3.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/87\">",
"     87",
"    </a>",
"    ]. Mycobacterial cell wall components may induce production of nitric oxide and reactive oxygen species, which have been implicated in DNA damage leading to carcinogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39673/abstract/88\">",
"     88",
"    </a>",
"    ]. Chronic inflammation may also enhance mutagenesis. In addition, immune suppression and radiation therapy for lung cancer may be associated with an increased risk of tuberculosis. Clinical and radiographic similarities between TB and malignancy may mislead diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1528583\">",
"    <span class=\"h2\">",
"     Chronic pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pulmonary aspergillosis can be a sequela of pulmonary tuberculosis. This is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22408?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of chronic pulmonary aspergillosis\", section on 'Underlying diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/57/25489?source=see_link\">",
"       \"Patient information: Tuberculosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/35/39475?source=see_link\">",
"       \"Patient information: Tuberculosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1529399\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical manifestations of tuberculosis (TB) include primary TB, reactivation TB, endobronchial TB, lower lung field TB infection, and tuberculoma. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with primary tuberculosis (TB), clinical manifestations have been observed in approximately one-third of cases. Symptoms include fever and chest pain. Retrosternal pain and dull interscapular pain have been ascribed to enlarged bronchial lymph nodes. The physical exam is generally normal. The most common chest radiograph abnormality in one large series was hilar adenopathy. Other manifestations include pleural effusions and pulmonary infiltrates. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Primary tuberculosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reactivation TB refers to reactivation of a previously dormant focus seeded at the time of the primary infection. The apical posterior segments of the lung are frequently involved (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54832 \" href=\"mobipreview.htm?11/9/11409\">",
"       image 1",
"      </a>",
"      ). Typically symptoms are insidious and may include cough, weight loss, fatigue, fever, night sweats, chest pain, dyspnea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hemoptysis; these findings are observed less frequently among patients &gt;60 years. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Reactivation tuberculosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endobronchial TB may develop via direct extension to the bronchi from an adjacent parenchymal focus (usually a cavity), or via spread of organisms to the bronchi via infected sputum. It can occur in patients with primary TB or reactivation TB, and was observed more frequently prior to the chemotherapy era. Symptoms may be acute or chronic; a barking cough has been described in approximately two-thirds of patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Endobronchial tuberculosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary complications of TB include hemoptysis, pneumothorax, bronchiectasis, extensive pulmonary destruction (including pulmonary gangrene), malignancy, and chronic pulmonary aspergillosis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Complications of tuberculosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110605938\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Nesli Basgoz, MD, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/1\">",
"      Stead WW, Kerby GR, Schlueter DP, Jordahl CW. The clinical spectrum of primary tuberculosis in adults. Confusion with reinfection in the pathogenesis of chronic tuberculosis. Ann Intern Med 1968; 68:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/2\">",
"      Buckner CB, Walker CW. Radiologic manifestations of adult tuberculosis. J Thorac Imaging 1990; 5:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/3\">",
"      POULSEN A. Some clinical features of tuberculosis. Acta Tuberc Scand 1957; 33:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/4\">",
"      Choyke PL, Sostman HD, Curtis AM, et al. Adult-onset pulmonary tuberculosis. Radiology 1983; 148:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/5\">",
"      Krysl J, Korzeniewska-Kosela M, M&uuml;ller NL, FitzGerald JM. Radiologic features of pulmonary tuberculosis: an assessment of 188 cases. Can Assoc Radiol J 1994; 45:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/6\">",
"      Khan MA, Kovnat DM, Bachus B, et al. Clinical and roentgenographic spectrum of pulmonary tuberculosis in the adult. Am J Med 1977; 62:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/7\">",
"      Barnes PF, Verdegem TD, Vachon LA, et al. Chest roentgenogram in pulmonary tuberculosis. New data on an old test. Chest 1988; 94:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/8\">",
"      Arango L, Brewin AW, Murray JF. The spectrum of tuberculosis as currently seen in a metropolitan hospital. Am Rev Respir Dis 1973; 108:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/9\">",
"      MacGregor RR. A year's experience with tuberculosis in a private urban teaching hospital in the postsanatorium era. Am J Med 1975; 58:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/10\">",
"      Mayock RL, MacGregor RR. Diagnosis, prevention and early therapy of tuberculosis. Dis Mon 1976; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/11\">",
"      Verver S, Bwire R, Borgdorff MW. Screening for pulmonary tuberculosis among immigrants: estimated effect on severity of disease and duration of infectiousness. Int J Tuberc Lung Dis 2001; 5:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/12\">",
"      Miller LG, Asch SM, Yu EI, et al. A population-based survey of tuberculosis symptoms: how atypical are atypical presentations? Clin Infect Dis 2000; 30:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/13\">",
"      Oursler KK, Moore RD, Bishai WR, et al. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis 2002; 34:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/14\">",
"      Wood R, Middelkoop K, Myer L, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007; 175:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/15\">",
"      P&eacute;rez-Guzm&aacute;n C, Vargas MH, Torres-Cruz A, Villarreal-Velarde H. Does aging modify pulmonary tuberculosis?: A meta-analytical review. Chest 1999; 116:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/16\">",
"      Mathur P, Sacks L, Auten G, et al. Delayed diagnosis of pulmonary tuberculosis in city hospitals. Arch Intern Med 1994; 154:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/17\">",
"      Bobrowitz ID. Active tuberculosis undiagnosed until autopsy. Am J Med 1982; 72:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/18\">",
"      Breen RA, Leonard O, Perrin FM, et al. How good are systemic symptoms and blood inflammatory markers at detecting individuals with tuberculosis? Int J Tuberc Lung Dis 2008; 12:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/19\">",
"      Lee P, Ho KK. Hyponatremia in pulmonary TB: evidence of ectopic antidiuretic hormone production. Chest 2010; 137:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/20\">",
"      Day JH, Charalambous S, Fielding KL, et al. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis 2006; 10:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/21\">",
"      POPPIUS H, THOMANDER K. Segmentary distribution of cavities; a radiologic study of 500 consecutive cases of cavernous pulmonary tuberculosis. Ann Med Intern Fenn 1957; 46:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/22\">",
"      Farman DP, Speir WA Jr. Initial roentgenographic manifestations of bacteriologically proven Mycobacterium tuberculosis. Typical or atypical? Chest 1986; 89:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/23\">",
"      LENTINO W, JACOBSON HG, POPPEL MH. Segmental localization of upper lobe tuberculosis; the rarity of anterior involvement. Am J Roentgenol Radium Ther Nucl Med 1957; 77:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/24\">",
"      Miller WT, MacGregor RR. Tuberculosis: frequency of unusual radiographic findings. AJR Am J Roentgenol 1978; 130:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/25\">",
"      Woodring JH, Vandiviere HM, Fried AM, et al. Update: the radiographic features of pulmonary tuberculosis. AJR Am J Roentgenol 1986; 146:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/26\">",
"      Marciniuk DD, McNab BD, Martin WT, Hoeppner VH. Detection of pulmonary tuberculosis in patients with a normal chest radiograph. Chest 1999; 115:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/27\">",
"      Im JG, Itoh H, Shim YS, et al. Pulmonary tuberculosis: CT findings--early active disease and sequential change with antituberculous therapy. Radiology 1993; 186:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/28\">",
"      Im JG, Itoh H, Han MC. CT of pulmonary tuberculosis. Semin Ultrasound CT MR 1995; 16:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/29\">",
"      De Backer AI, Mortel&eacute; KJ, De Keulenaer BL, Parizel PM. Tuberculosis: epidemiology, manifestations, and the value of medical imaging in diagnosis. JBR-BTR 2006; 89:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/30\">",
"      Hara T, Kosaka N, Suzuki T, et al. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest 2003; 124:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/31\">",
"      Hoheisel G, Chan BK, Chan CH, et al. Endobronchial tuberculosis: diagnostic features and therapeutic outcome. Respir Med 1994; 88:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/32\">",
"      Salkin D, Cadden AV, Edson RC. The natural history of tuberculous tracheobronchitis. Am Rev Tuberc 1943; 47:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/33\">",
"      Wilson NJ. Bronchoscopic observations in tuberculosis tracheobronchitis: Clinical and pathological correlations. Dis Chest 1945; 11:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/34\">",
"      MacRAE DM, HILTZ JE, QUINLAN JJ. Bronchoscopy in a sanatorium; a review of 522 consecutive bronchoscopies. Am Rev Tuberc 1950; 61:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/35\">",
"      AUERBACH O. Tuberculosis of the trachea and major bronchi. Am Rev Tuberc 1949; 60:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/36\">",
"      Shim YS. Endobronchial tuberculosis. Respirology 1996; 1:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/37\">",
"      Kashyap S, Mohapatra PR, Saini V. Endobronchial tuberculosis. Indian J Chest Dis Allied Sci 2003; 45:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/38\">",
"      LINCOLN EM, HARRIS LC, BOVORNKITTI S, CARRETERO R. The course and prognosis of endobronchial tuberculosis in children. Am Rev Tuberc 1956; 74:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/39\">",
"      Frostad S. Lymph node perforation through the bronchial tree in children with primary tuberculosis. Acta Tuberc Scand 1959; 47:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/40\">",
"      Lee JH, Park SS, Lee DH, et al. Endobronchial tuberculosis. Clinical and bronchoscopic features in 121 cases. Chest 1992; 102:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/41\">",
"      Ip MS, So SY, Lam WK, Mok CK. Endobronchial tuberculosis revisited. Chest 1986; 89:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/42\">",
"      Seiden HS, Thomas P. Endobronchial tuberculosis and its sequelae. Can Med Assoc J 1981; 124:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/43\">",
"      Caglayan S, Coteli I, Acar U, Erkin S. Endobronchial tuberculosis simulating foreign body aspiration. Chest 1989; 95:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/44\">",
"      Matthews JI, Matarese SL, Carpenter JL. Endobronchial tuberculosis simulating lung cancer. Chest 1984; 86:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/45\">",
"      Van den Brande PM, Van de Mierop F, Verbeken EK, Demedts M. Clinical spectrum of endobronchial tuberculosis in elderly patients. Arch Intern Med 1990; 150:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/46\">",
"      So SY, Lam WK, Sham MK. Bronchorrhea. A presenting feature of active endobronchial tuberculosis. Chest 1983; 84:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/47\">",
"      Williams DJ, York EL, Nobert EJ, Sproule BJ. Endobronchial tuberculosis presenting as asthma. Chest 1988; 93:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/48\">",
"      Albert RK, Petty TL. Endobronchial tuberculosis progressing to bronchial stenosis. Fiberoptic bronchoscopic manifestations. Chest 1976; 70:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/49\">",
"      NEMIR RL, CARDONA J, LACOIUS A, DAVID M. PREDNISONE THERAPY AS AN ADJUNCT IN THE TREATMENT OF LYMPH NODE-BRONCHIAL TUBERCULOSIS IN CHILDHOOD. A DOUBLE-BLIND STUDY. Am Rev Respir Dis 1963; 88:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/50\">",
"      Chan HS, Sun A, Hoheisel GB. Endobronchial tuberculosis--is corticosteroid treatment useful? A report of 8 cases and review of the literature. Postgrad Med J 1990; 66:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/51\">",
"      Low SY, Hsu A, Eng P. Interventional bronchoscopy for tuberculous tracheobronchial stenosis. Eur Respir J 2004; 24:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/52\">",
"      Caligiuri PA, Banner AS, Jensik RJ. Tuberculous main-stem bronchial stenosis treated with sleeve resection. Arch Intern Med 1984; 144:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/53\">",
"      Sawada S, Fujiwara Y, Furui S, et al. Treatment of tuberculous bronchial stenosis with expandable metallic stents. Acta Radiol 1993; 34:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/54\">",
"      Yencha MW, Linfesty R, Blackmon A. Laryngeal tuberculosis. Am J Otolaryngol 2000; 21:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/55\">",
"      SEGARRA F, SHERMAN DS, RODRIGUEZ-AGUERO J. Lower lung field tuberculosis. Am Rev Respir Dis 1963; 87:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/56\">",
"      Chang SC, Lee PY, Perng RP. Lower lung field tuberculosis. Chest 1987; 91:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/57\">",
"      Parmar MS. Lower lung field tuberculosis. Am Rev Respir Dis 1967; 96:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/58\">",
"      STEELE JD. THE SOLITARY PULMONARY NODULE. REPORT OF A COOPERATIVE STUDY OF RESECTED ASYMPTOMATIC SOLITARY PULMONARY NODULES IN MALES. J Thorac Cardiovasc Surg 1963; 46:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/59\">",
"      Stead WW. Tuberculosis among elderly persons: an outbreak in a nursing home. Ann Intern Med 1981; 94:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/60\">",
"      Johnston H, Reisz G. Changing spectrum of hemoptysis. Underlying causes in 148 patients undergoing diagnostic flexible fiberoptic bronchoscopy. Arch Intern Med 1989; 149:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/61\">",
"      McGuinness G, Beacher JR, Harkin TJ, et al. Hemoptysis: prospective high-resolution CT/bronchoscopic correlation. Chest 1994; 105:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/62\">",
"      Conlan AA, Hurwitz SS, Krige L, et al. Massive hemoptysis. Review of 123 cases. J Thorac Cardiovasc Surg 1983; 85:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/63\">",
"      Rasmussen V, Moore WD. Continued observations on hemoptysis. Edinburgh Med J 1869; 15:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/64\">",
"      THOMPSON JR. Mechanisms of fatal pulmonary hemorrhage in tuberculosis. Am J Surg 1955; 89:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/65\">",
"      Corey R, Hla KM. Major and massive hemoptysis: reassessment of conservative management. Am J Med Sci 1987; 294:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/66\">",
"      Muthuswamy PP, Akbik F, Franklin C, et al. Management of major or massive hemoptysis in active pulmonary tuberculosis by bronchial arterial embolization. Chest 1987; 92:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/67\">",
"      Bobrowitz ID, Ramakrishna S, Shim YS. Comparison of medical v surgical treatment of major hemoptysis. Arch Intern Med 1983; 143:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/68\">",
"      Yeoh CB, Hubaytar RT, Ford JM, Wylie RH. Treatment of massive hemorrhage in pulmonary tuberculosis. J Thorac Cardiovasc Surg 1967; 54:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/69\">",
"      Amirana M, Frater R, Tirschwell P, et al. An aggressive surgical approach to significant hemoptysis in patients with pulmonary tuberculosis. Am Rev Respir Dis 1968; 97:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/70\">",
"      Uflacker R, Kaemmerer A, Picon PD, et al. Bronchial artery embolization in the management of hemoptysis: technical aspects and long-term results. Radiology 1985; 157:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/71\">",
"      Berry FB. Tuberculous pyopneumothorax with pyogenic infection. J Thorac Surg 1932; 2:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/72\">",
"      WILDER RJ, BEACHAM EG, RAVITCH MM. Spontaneous pneumothorax complicating cavitary tuberculosis. J Thorac Cardiovasc Surg 1962; 43:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/73\">",
"      Ihm HJ, Hankins JR, Miller JE, McLaughlin JS. Pneumothorax associated with pulmonary tuberculosis. J Thorac Cardiovasc Surg 1972; 64:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/74\">",
"      Akto��u S, Yorgancioglu A, Cirak K, et al. Clinical spectrum of pulmonary and pleural tuberculosis: a report of 5,480 cases. Eur Respir J 1996; 9:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/75\">",
"      Hussain SF, Aziz A, Fatima H. Pneumothorax: a review of 146 adult cases admitted at a university teaching hospital in Pakistan. J Pak Med Assoc 1999; 49:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/76\">",
"      Auerbach O, Lipstein S. Bronchopleural fistulas complication pulmonary tuberculosis. J Thorac Surg 1939; 8:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/77\">",
"      Rilance AB, Gerstl B. Bronchiectasis secondary to puomonary tuberculosis. Am Rev Tuberc 1943; 48:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/78\">",
"      Roberts JC, Blair LG. Bronchiectasis in primary tuberculosis. Lancet 1950; 1:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/79\">",
"      Rosenzweig DY, Stead WW. The role of tuberculosis and other forms of bronchopulmonary necrosis in the pathogenesis of bronchiectasis. Am Rev Respir Dis 1966; 93:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/80\">",
"      COHEN AG. Atelectasis of the right middle lobe resulting from perforation of tuberculous lymph nodes into bronchi in adults. Ann Intern Med 1951; 35:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/81\">",
"      CURTIS JK. The significance of bronchiectasis associated with pulmonary tuberculosis. Am J Med 1957; 22:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/82\">",
"      Brock RC. Post-tuberculous broncho-stenosis and bronchiectasis of the middle lobe. Thorax 1950; 5:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/83\">",
"      Bobrowitz ID, Rodescu D, Marcus H, Abeles H. The destroyed tuberculous lung. Scand J Respir Dis 1974; 55:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/84\">",
"      Palmer PE. Pulmonary tuberculosis--usual and unusual radiographic presentations. Semin Roentgenol 1979; 14:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/85\">",
"      Khan FA, Rehman M, Marcus P, Azueta V. Pulmonary gangrene occurring as a complication of pulmonary tuberculosis. Chest 1980; 77:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/86\">",
"      Lorenz R, Kraman SS. Intracavitary mass in a patient with far-advanced tuberculosis. Chest 1982; 82:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/87\">",
"      Brenner AV, Wang Z, Kleinerman RA, et al. Previous pulmonary diseases and risk of lung cancer in Gansu Province, China. Int J Epidemiol 2001; 30:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39673/abstract/88\">",
"      Falagas ME, Kouranos VD, Athanassa Z, Kopterides P. Tuberculosis and malignancy. QJM 2010; 103:461.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7026 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-50E636C042-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39673=[""].join("\n");
var outline_f38_47_39673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1529399\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1528649\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Primary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Radiographic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H146930397\">",
"      - Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reactivation tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Presentation in older adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Physical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Radiographic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Endobronchial tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Physical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Radiographic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1528626\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H146930772\">",
"      - Laryngeal tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Lower lung field tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Tuberculoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      COMPLICATIONS OF TUBERCULOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hemoptysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Bronchiectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Extensive pulmonary destruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13013757\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1528583\">",
"      Chronic pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1529399\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110605938\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7026\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7026|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/9/11409\" title=\"diagnostic image 1\">",
"      TB chest radiograph 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?40/40/41606\" title=\"diagnostic image 2\">",
"      TB chest radiograph 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/60/18373\" title=\"diagnostic image 3\">",
"      TB chest radiograph 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7026|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/30/26093\" title=\"table 1\">",
"      Comparison TB clinical features",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22408?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44537?source=related_link\">",
"      Diagnostic evaluation and management of the solitary pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22378?source=related_link\">",
"      Microbiology and pathogenesis of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/35/39475?source=related_link\">",
"      Patient information: Tuberculosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/57/25489?source=related_link\">",
"      Patient information: Tuberculosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/47/22261?source=related_link\">",
"      Tuberculous pleural effusions in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12856?source=related_link\">",
"      Tuberculous pleural effusions in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_47_39674="Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology";
var content_f38_47_39674=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39674/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39674/contributors\">",
"     Patrick C Ma, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39674/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39674/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39674/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/47/39674/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/47/39674/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/47/39674/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important goals of cancer research include the discovery of novel cellular targets to exploit for novel targeted treatments, new biomarkers for early cancer detection, and to provide a better classification of cancers for prognostication and treatment selection.",
"   </p>",
"   <p>",
"    Toward this end, a significant effort has been devoted to understanding the molecular basis of carcinogenesis and the biologic behavior of human cancers. Progress has been slow, reflecting the complexity of the molecular alterations that characterize tumor cells. Carcinogenesis is a multistep process involving genetic and epigenetic events that result in altered expression of numerous genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/1\">",
"     1",
"    </a>",
"    ]. Confounding this complexity, many of the so-called oncogenes and tumor suppressor genes are signaling molecules, which control the expression of a subset of downstream genes.",
"   </p>",
"   <p>",
"    Cells respond to environmental signals by modulating the expression of genes contained within the nucleus. When genes are activated, they are transcribed to generate messenger RNA (mRNA), which is transported from the nucleus to the cytoplasm and translated into protein by the ribosomes.",
"   </p>",
"   <p>",
"    Approximately 3 to 5 percent of genes are active in a particular cell, even though all cells have the same information contained in their DNA. Most of the genome is selectively repressed, a property that is governed by the regulation of gene expression, mostly at the level of transcription (ie, the production of messenger RNA from the DNA). In response to a cellular perturbation, changes in gene expression take place that result in the expression of hundreds of gene products and the suppression of others. This molecular heterogeneity is thought to underlie, at least in part, the variability in outcome and response to therapy that characterizes tumors of different histology.",
"   </p>",
"   <p>",
"    Significant variability also exists for tumors of a specific histologic type. In general, clinical management decisions and prognostic estimates are based solely upon histopathologic analysis of tumor tissue. However, tumor behavior cannot be adequately understood through the analysis of one or a small numbers of genes, particularly for the common solid tumors.",
"   </p>",
"   <p>",
"    The examination of multiple expressed genes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteins provides more useful information for both classification and prognostication of individual tumors. The development of microarray methodology, which permits the expression of thousands of genes to be assayed simultaneously, represents a powerful technique to read the \"molecular signature\" of an individual patient's tumor. This process is termed gene expression profiling (GEP). Analyzing gene expression patterns across individual patients with the \"same\" disease may reveal molecular differences. Such classification may allow better treatment selection and prognostication. Proteomics is a slightly different but related approach, in which the expressed proteins of a tissue or cell type are assayed rather than the genes themselves.",
"   </p>",
"   <p>",
"    A description of the methods used for GEP and proteomics, as well as a brief overview of some potential clinical applications, will be presented here. A brief description of the new development of microRNA (miRNA) profiling in cancer diagnosis and prognosis will also be included. More detailed discussion of the applications of these techniques to specific tumor types is discussed in the appropriate tumor topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GEP AND DNA MICROARRAY ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional method of measuring the level of expression of a single gene is by assaying RNA by Northern blot analysis. DNA microarray analysis uses the same principles to simultaneously measure the expression level of thousands of genes on a platform called a microarray. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are several stages to performing a microarray analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preparation of the microarray",
"     </li>",
"     <li>",
"      Generation of fluorescent targets from the RNA of the samples",
"     </li>",
"     <li>",
"      Hybridization to the probes",
"     </li>",
"     <li>",
"      Data acquisition: scanning of the signal intensity emanating from the hybridized labeled probes",
"     </li>",
"     <li>",
"      Data analysis: the extraction of biologically useful information from the vast quantity of data that is generated from microarray analysis. This aspect is often the most challenging component of GEP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preparation of the microarray",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DNA array consists of an orderly arrangement of DNA spots on a glass slide or chip. In its simplest form, a few dozen complementary DNAs (cDNAs) or oligonucleotides corresponding to particular genes are immobilized onto the substrate in a known order within the grid.",
"   </p>",
"   <p>",
"    In highly-sophisticated microarray \"chips\", up to hundreds of thousands of unique oligonucleotide probes, representing thousands of known genes or expressed sequence tags (ESTs), are synthesized in a microgrid on a glass substrate about the size of a thumbnail. ESTs are segments of expressed genes that have been sequenced, but do not correspond to known genes.",
"   </p>",
"   <p>",
"    Each oligonucleotide probe, which is specific for a particular gene, is located on a precise place within the microgrid; this is the probe cell. Each probe cell is very small, about 24 microns by 24 microns, and contains millions of copies of each specific oligonucleotide. A particular gene (eg, the gene encoding thymidylate synthetase) may be represented on the microgrid by 20 or more probe cells, called a probe set. The oligonucleotide probes (usually 15 to 25 nucleotides in length) in each probe cell of the probe set may differ from each other, some corresponding to the 5' end of the mRNA sequence, some the middle, and some the 3' end. This gives the sample RNA a broad range of sequences with which to hybridize.",
"   </p>",
"   <p>",
"    Various sources of DNA may be used as probes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cDNA microarray the DNA spots are composed of DNA sequences (cDNA clones, or ESTs) that are extracted from plasmid-containing bacterial cultures; they correspond in sequence to specific genes derived from the UniGene public database. These polymerase chain reaction (PCR)-amplified ESTs or whole cDNA clones, usually 500 to 2000 base pairs (bp) in length, are deposited on the microarray surface using high-speed robotics.",
"     </li>",
"     <li>",
"      For an oligonucleotide (oligo) array, oligonucleotide sequences, typically 15 to 25 bp in length, that are unique to the genes of interest, are synthesized in situ on the chip itself (one popular example is the Affymetrix&reg; GeneChip). As with cDNA arrays, the information needed to construct the oligo probes is derived from published databases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the basic principles underlying cDNA and oligo microarrays are similar, there are two significant differences. One is the amount of RNA that is required from patient samples for each experiment. In general, cDNA microarray experiments require more than 50 micrograms of total RNA from target tissues, while 5 micrograms may be sufficient for an oligo array experiment.",
"   </p>",
"   <p>",
"    The second difference has to do with the way control or reference samples are handled. In a cDNA microarray, a control sample (eg, normal as compared to diseased tissue) is simultaneously analyzed along with the test sample on the same chip. Gene expression is estimated by comparing the RNA content of the test and control samples, and the results are then reported as a ratio. By contrast, in the oligo-based approach, a test sample on one oligo chip is compared to a reference or control sample on another chip, and interpretation requires comparing the levels from the test sample to those of the control or reference sample.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Target preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;To obtain the test samples, messenger RNA (mRNA) is extracted from the patient's tissue. This mRNA represents all the genes expressed in that tissue at that time. The mRNA is then converted to cDNA using reverse transcriptase and deoxyribonucleotides and is labeled with fluorescent dyes. The labeled nucleic acids (in some cases cDNA and in some cases RNA) derived from the sample are called targets.",
"   </p>",
"   <p>",
"    The process of generating the targets can be illustrated by the methods used to compare the GEP of tumor and normal cells for a cDNA microarray experiment. Initially, total RNA or mRNA is extracted from the tumor tissue, and reverse transcribed into cDNA using reverse transcriptase in the presence of fluorescently labeled deoxynucleotides (typically using the fluorochrome Cy3 [rhodamine] which emits red light upon excitation at a wavelength of 565 nm). This results in the generation of a cDNA into which the fluorescently labeled deoxynucleotides are incorporated.",
"   </p>",
"   <p>",
"    Upon completion of the reaction, all the RNA in the sample will have been converted into fluorescently labeled cDNA. The greater the abundance of a particular mRNA sequence, the greater the amount of labeled cDNA synthesized during reverse transcription.",
"   </p>",
"   <p>",
"    In a parallel reaction, an equivalent amount of RNA isolated from normal cells is also reverse transcribed, but differentially labeled using a different fluorochrome (often Cy5 [",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    ] which emits green light upon excitation at a wavelength of 670 nm).",
"   </p>",
"   <p>",
"    Differential labeling is not necessary for oligo arrays. Instead, the sample mRNA is first reverse transcribed into cDNA in the absence of radiolabeled nucleotides. This single-stranded DNA is then converted to double-stranded cDNA, which is in turn transcribed into cRNA in the presence of biotinylated nucleotides. This additional step amplifies the target mRNA approximately 50-fold. The fluorescent tag is added after hybridization by the use of an avidin-conjugated fluorophore (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hybridization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The labeled sample or target is then placed onto the array and hybridization based on complementary base pairing is allowed to take place. The more mRNAs in the original sample (ie, the higher the expression of a particular gene), the more fluorescently-labeled material corresponding to that gene is in the target and the more labeled material will be hybridized at that gene's location on the array.",
"   </p>",
"   <p>",
"    For the cDNA array, the differentially labeled test and reference cDNA samples are mixed in equal amounts, and incubated with the microarray slide until hybridization is complete. The labeled sequences of the target mixture hybridize to the homologous sequence of the gene (ie, the probe) on the array. The amount of RNA in the original sample dictates the extent of binding to a specific probe. Because the test and normal samples are differentially labeled, the relative amount of binding in the test sample relative to control is determined by detecting the degree and type of fluorescence (ie, red for the tumor tissue and green for the control).",
"   </p>",
"   <p>",
"    For oligo chip array experiments, the biotinylated cRNA is hybridized to the oligo probes on the chip, and followed by binding to an avidin-conjugated fluorophore.",
"   </p>",
"   <p>",
"    In the final microarray (both cDNA and oligo), each cell or spot on the microarray chip (sometimes termed a \"feature\") represents the quantification of gene expression for a given gene in a given sample. On the microarray, the individual samples are shown in one direction, while the specific genes are shown in the other. As an example, a microarray is shown in the figure in which each row (ie, from left to right) represents a patient sample, while each column (ie, top to bottom) represents a specific gene (",
"    <a class=\"graphic graphic_figure graphicRef74048 \" href=\"mobipreview.htm?25/36/26183\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Data acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using fluorescent detectors coupled to computers equipped with specialized software, the amount of gene expression for thousands of genes and ESTs can be estimated simultaneously, generating a gene expression profile (GEP) for that sample.",
"   </p>",
"   <p>",
"    Once hybridization is complete, the arrays are washed, and a laser beam is used to excite the fluorophores that are linked to the hybridized target molecules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     cDNA microarrays",
"    </span>",
"    &nbsp;&mdash;&nbsp;For cDNA microarrays, the degree and type of fluorescence is assessed using a laser scanner that is capable of detecting and quantifying the amount of light emitted in the green and the red wavelength, then converting this to a digital image.",
"   </p>",
"   <p>",
"    Four possible scenarios are outlined below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a gene is underexpressed in tumor, many more RNA copies of this gene will be present in normal compared to tumor tissue, and the spot that corresponds to this gene on the microarray will appear green.",
"     </li>",
"     <li>",
"      In contrast, if the gene is expressed at a higher level in tumor tissue, more mRNA will be present in the tumor compared to normal tissue, and the spot on the microarray that corresponds to this gene will appear red.",
"     </li>",
"     <li>",
"      If genes are similarly expressed in normal and tumor tissue, competition between the two probes will result in an equal amount of hybridization with red and green-labeled probes, and the spot will appear yellow on the microarray.",
"     </li>",
"     <li>",
"      If a gene is expressed in neither tumor nor normal tissue, there will be no hybridization to this spot on the array, and the spot will appear black.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This information can be quantified by calculating the ratio of both signal intensities. Thus, if the level of gene expression is similar in tumor and normal tissue, the ratio is 1. In contrast, genes that are more highly expressed in the tumor (upregulated) have a ratio greater than 1, while downregulated genes have a ratio that is less than 1. The absolute level of gene expression in test as compared to control samples is of importance in selecting genes of interest. Genes that are overexpressed or underexpressed to a level threefold or greater are more likely to be of interest than those whose expression differs by a lesser amount.",
"   </p>",
"   <p>",
"    Expression levels of each gene can be compared across many tissue or tumor samples. In this way, groups or clusters of genes can be identified whose expression varies in similar ways. The most common mathematical algorithm used to compare GEPs is aggregative hierarchical clustering, which is described in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Oligo arrays",
"    </span>",
"    &nbsp;&mdash;&nbsp;For oligo arrays, the abundance of a target molecule on a certain spot is estimated by scanning the intensity of emitted fluorescence of the linked reported molecules. Raw data from two microarrays (one from diseased tissue and another from normal or control tissue) must then be compared to identify genes that are differentially expressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Data analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of analysis of microarray data is to extract \"biologic order\" based upon similarities and differences in gene expression. Data normalization is necessary as the first step for both cDNA and oligo arrays. The signal intensity must be adjusted to a common standard to correct for differences in background noise or the efficiency of data acquisition.",
"   </p>",
"   <p>",
"    After normalization, the raw GEP levels are presented as expression ratios (test versus control sample) that are typically log-transformed to simplify the presentation of differences (eg, threefold increase in expression, twofold decrease in expression of the test sample relative to control).",
"   </p>",
"   <p>",
"    Defining the purpose of the GEP experiment is critical. In oncology, microarray experiments have focused on the following objectives:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gene discovery &mdash; Identification of candidate genes that are differentially expressed in normal as compared to tumor tissue, or between different tumor samples is a major goal. The identification of these genes may help to define molecular pathogenesis, pathways of drug resistance, or new potential targets for therapy (see below).",
"      <br/>",
"      <br/>",
"      Discovery of such candidate genes may be facilitated by comparative genomic hybridization techniques, in which chromosomal regions, which may harbor tumor suppressors",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      oncogenes, may be scanned for the presence of significant genetic deletions or amplifications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Molecular classification &mdash; The use of GEP profiles of known disease classes to accurately predict the biologic group, diagnostic category, or prognostic classification of an unknown tumor sample is termed",
"      <strong>",
"       class prediction",
"      </strong>",
"      . In contrast,",
"      <strong>",
"       class discovery",
"      </strong>",
"      refers to the identification of new molecular disease classes that may be relevant to future disease classification, prognostication,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treatment selection. Because disease classes are not predefined, these studies aim to determine whether discrete, previously unrecognized molecular subsets of a disease entity can be identified based solely upon the GEP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Selecting genes of interest",
"    </span>",
"    &nbsp;&mdash;&nbsp;When comparing the GEP of samples to identify genes that are differentially expressed, candidate genes may be selected by several methods. An arbitrary, fold-based difference in expression (eg, &gt;2-, 5-, or 10-fold difference in spot intensity), or a statistical test, such as the t-test (for two samples) or F-test (for three or more samples) can be used to select those genes that are significantly differentially expressed among patients or experiments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These genes then undergo further analysis to confirm overexpression, typically by real-time polymerase chain reaction (PCR) techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/2\">",
"     2",
"    </a>",
"    ]. The next step is to group or cluster the genes of interest based upon similarity of expression within a given tissue or tumor in order to identify genes that may be coregulated, and therefore, functionally related [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clustering of similarly expressed genes may generate a pattern or profile that separates tumors of distinct phenotypes, classes or disease stage. These clusters are identified by mathematical algorithms.",
"   </p>",
"   <p>",
"    The organization of the sample according to clusters can be performed in one of two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unsupervised, ie, not based upon any prior information regarding the analyzed objects. Unsupervised analysis utilizes information provided by all genes that are expressed in the tissue.",
"     </li>",
"     <li>",
"      Supervised, ie, based upon prior known information, and a preselected group of genes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both approaches can be applied to the same data set for different purposes. However, the supervised method is a better method to prospectively identify tumors that belong to a predefined clinically important subgroup (ie, class prediction).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Unsupervised clustering",
"    </span>",
"    &nbsp;&mdash;&nbsp;In unsupervised cluster analysis, the statistical algorithm is not trained to recognize a specific gene expression pattern from any previously known class or grouping of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/2\">",
"     2",
"    </a>",
"    ]. Unsupervised clustering is often hierarchical (ie, a classification with nested classes resembling a phylogenetic tree), or it may be nonhierarchical (classification into clusters without specifying the relationship between individual members of a class). In turn, hierarchical clustering may be agglomerative (starting from single members and their relationship with one another, and growing into bigger classes) or divisive (a technique that starts by grouping all members into one class, and subsequently breaking the class into smaller groups).",
"   </p>",
"   <p>",
"    Hierarchical agglomerative clustering is the most commonly used method in gene expression analysis. It begins by identifying a single gene pair with the most similar expression across patients or experiments. These genes are then \"fused\" (subsequently represented by the mean of their two expression levels); this value is then considered a single element in further analyses. The process of \"fusing\" is repeated until all elements are included in the analysis, and a dendrogram is assembled (",
"    <a class=\"graphic graphic_figure graphicRef81774 \" href=\"mobipreview.htm?18/2/18471\">",
"     figure 2",
"    </a>",
"    ). The dendrogram resembles an evolutionary tree, where terminal branches depict closely related specimens. Within this single hierarchical tree, the intercluster distance (branch length of the dendrogram) directly correlates with dissimilarity in gene expression. Similarly expressed genes are ordered next to each other, and visualized as color coded rows (red for overexpressed, green for underexpressed).",
"   </p>",
"   <p>",
"    In this way, genes are organized into functional categories, which may reveal clinically important and previously unknown molecular classes within one single disease group (ie, class discovery). A commonly used strategy for outcome prediction is to select cases with known outcome (eg, tumors that did and did not respond to a particular therapy).",
"   </p>",
"   <p>",
"    Validation is an important component of unsupervised clustering. Cases should be randomly divided into two groups. The first group, the training set, is used to discover a genomic predictive test, and the second, referred to as the validation set, is used to confirm the results and estimate its predictive accuracy in independent cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Supervised clustering",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to unsupervised cluster analysis, supervised algorithms predict classes based on previously known information. The procedure begins with training a machine, using a machine-learning algorithm, to recognize specific gene expression patterns that are associated with known patient groups or clinical outcomes (ie, normal versus tumor tissue, specific disease types, responders versus non-responders, relapse versus no relapse).",
"   </p>",
"   <p>",
"    Several algorithms are available, including support vector machines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/8\">",
"     8",
"    </a>",
"    ], weighted voting methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], nearest neighbor classification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], and artificial neural networks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/13\">",
"     13",
"    </a>",
"    ]. The goal is for the machine to learn to distinguish between members and non-members of a specific class based upon expression data, and construct a classifier or discriminator that will be used to accurately assign an unknown sample to one of these predefined classes. Such a classifier may then be used to assign certain genes to functional classes, and diseases into predefined categories that might predict diagnosis, prognosis, stage, or the response to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/2,14,15\">",
"     2,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The unsupervised method is less biased and better suited to reveal previously unrecognized tumor subtypes within morphologically similar cancers based upon similarities in global GEP (ie, class discovery). Although molecular subgroups may or may not reflect biologically or clinically important distinctions, GEPs are strikingly accurate in separating tumors along known classification lines in many cases. As examples, unsupervised clustering of breast cancer specimens consistently separates tumors into estrogen receptor (ER)-positive and ER-negative clusters, indicating that ER status has a major impact on the GEP of breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In a similar way, acute leukemia can be separated into myeloid (AML) and lymphoblastic (ALL) subtypes on the basis of GEP alone (",
"    <a class=\"graphic graphic_figure graphicRef74048 \" href=\"mobipreview.htm?25/36/26183\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATIONS OF DNA MICROARRAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;GEP is a powerful tool to identify genes and pathways that are aberrantly expressed during carcinogenesis. While these discoveries enhance our understanding of molecular pathogenesis, they can also suggest novel therapeutic targets, provide information about drug resistance pathways, and refine prognostic classifications.",
"   </p>",
"   <p>",
"    A major problem in clinical oncology is the heterogeneous response of histologically similar tumors to treatments such as cytotoxic chemotherapy. With the exception of",
"    <span class=\"nowrap\">",
"     estrogen/progesterone",
"    </span>",
"    receptor, and HER2 (c-erbB-2) expression in breast cancer (for hormonal therapy and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , respectively), EGFR kinase domain mutations and genomic amplification in lung cancer (in EGFR targeted inhibitors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    ), and K-ras mutations in colon cancer (lack of response to EGFR-targeted antagonists), there are no other single molecules that are clinically useful predictors of response validated for any form of anticancer therapy.",
"   </p>",
"   <p>",
"    Encouraging emerging data suggest that prediction of response to chemotherapy or biologically targeted agents may be possible by analyzing gene expression profiles (GEPs). With rapid advances in the DNA microarray technologies and more sophisticated studies, microarray analysis has started to make ways into clinical trials and practices in oncology.",
"   </p>",
"   <p>",
"    Several examples of the potential application of GEPs in clinical oncology are described here to illustrate the utility of this technology in common solid tumors and hematologic malignancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first report to show that GEPs could be used to classify tumors analyzed a group of acute leukemias (",
"    <a class=\"graphic graphic_figure graphicRef74048 \" href=\"mobipreview.htm?25/36/26183\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/14\">",
"     14",
"    </a>",
"    ]. Based upon gene expression patterns, acute myeloid leukemia (AML) could be distinguished from acute lymphoblastic leukemia (ALL) without standard histology information. Similarly, B-cell versus T-cell ALL could be separated based on GEP. This study served as proof of principle that clinically useful classifications could be made simply by gene expression patterns. In another report, a case with equivocal histology by standard criteria was accurately classified by gene analysis, demonstrating the potential utility of GEP beyond standard histologic and immunocytochemical methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Myeloid sarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Others have shown that GEP can distinguish among prognostically important subgroups of children with ALL and adults with AML, in some cases identifying those who eventually fail therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. If these findings are confirmed by others, the logical next step is to apply a more intense initial treatment strategy to such patients, selected on the basis of their GEP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/58/4009?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\", section on 'Cytogenetics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It may also be possible to screen for agents capable of inducing leukemic cell differentiation through changes in their GEP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/23\">",
"     23",
"    </a>",
"    ]. A major caveat is that gene expression profiles of clinical samples may differ significantly from those seen in cell lines representing the corresponding leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential application of GEP in men at risk for prostate cancer is the identification of biomarkers that can help select men with a borderline elevation in serum prostate specific antigen (PSA) for biopsy. In addition, GEP might be used to identify men whose early stage tumors are destined to recur and thus would benefit from more aggressive therapy.",
"   </p>",
"   <p>",
"    GEP has been used to identify several genes (eg, hepsin and pim-1) that are upregulated in prostate cancer compared to benign prostatic hyperplasia and normal prostate tissue, and some are highly correlated with clinical outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/25-30\">",
"     25-30",
"    </a>",
"    ]. Investigators have found a &ge;3-fold difference in expression in over 3000 genes when nonrecurrent prostate cancers were compared to metastatic tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Colon cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serine phosphatase PRL-3 is consistently upregulated in metastatic as compared to non-metastatic colorectal cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/31\">",
"     31",
"    </a>",
"    ]. The finding that metastatic potential appears to be encoded in the primary has challenged the notion that metastases arise from rare cells that have acquired the ability to metastasize [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GEP is under study as a way to improve prognostication, and perhaps, individualize adjuvant therapy recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/33\">",
"     33",
"    </a>",
"    ]. An area of intense study is the use of GEP to predict which patients with node-negative resected colon cancer are at a relatively higher risk of relapse, and thus, might benefit from adjuvant chemotherapy, as is typically recommended for patients with node-positive disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;A molecular classification for breast cancer has been proposed based upon GEP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/16-18,34-36\">",
"     16-18,34-36",
"    </a>",
"    ]. Luminal (mainly estrogen receptor [ER] positive), basal-like (mostly ER-negative), normal-like, and erbB2+ (mostly HER-2 overexpressing, ER-negative) subgroups have been identified, and have different prognoses.",
"   </p>",
"   <p>",
"    A major area of investigation is the use of such molecular profiling to predict response to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/37-42\">",
"     37-42",
"    </a>",
"    ]. The GEPs of breast cancers that respond best to neoadjuvant (preoperative) chemotherapy (ie, basal-like, erbB2+) differ from those of nonresponding or resistant tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/37-39,42-44\">",
"     37-39,42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analysis of GEP can also distinguish sporadic breast cancers from those associated with BRCA mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/45\">",
"     45",
"    </a>",
"    ]. Perhaps more importantly, GEP can also permit stratification of defined subgroups (ie, those with axillary lymph node-negative breast cancer or grade 2 tumors) into prognostically separate categories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/46-52\">",
"     46-52",
"    </a>",
"    ]. In at least some reports, outcome prediction by GEP outperforms existing prognostic classifications. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6503?source=see_link\">",
"     \"Prognostic molecular profiles of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GEP analysis by DNA microarray is available in patients with breast cancer (the 21-gene recurrence score assay, like Oncotype DX&trade;) to quantify the likelihood of a breast cancer recurrence in women with newly diagnosed, node-negative hormone receptor-positive early stage breast cancer. The assay is designed to identify those women whose risk of recurrence is low enough to justify the omission of chemotherapy and use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    alone as systemic adjuvant therapy.",
"   </p>",
"   <p>",
"    Although commercially available, the benefit of using 21-gene recurrence score assays (eg, Oncotype DX&trade;) to select the adjuvant therapy strategy has not been tested in a prospective trial. Such an approach is being evaluated in the phase III Trial Assigning IndividuaLized Options for Treatment (Rx) (the TAILORx clinical trial), sponsored by the National Cancer Institute and led by the Eastern Cooperative Oncology Group (ECOG). This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6503?source=see_link&amp;anchor=H3#H3\">",
"     \"Prognostic molecular profiles of breast cancer\", section on 'Recurrence score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Lung carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;GEP can reliably separate lung tumors into their morphologic categories of squamous, large cell, small cell, and adenocarcinoma (",
"    <a class=\"graphic graphic_figure graphicRef81774 \" href=\"mobipreview.htm?18/2/18471\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. GEP may have even more utility in the assessment of patients with non-small cell lung cancers (NSCLCs) and similar histology.",
"   </p>",
"   <p>",
"    Several investigators have attempted to subclassify these tumors by correlating GEP patterns with clinicopathologic variables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/53,56,57\">",
"     53,56,57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A series that included 41 lung adenocarcinomas identified three prognostically separate subgroups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/53\">",
"       53",
"      </a>",
"      ]. The genes involved in this classification included thyroid transcription factor, hepsin, cathepsin L, vascular endothelial growth factor C (VEGF-C), and the intercellular adhesion molecule-1 (ICAM-1).",
"     </li>",
"     <li>",
"      In another report of 139 lung adenocarcinomas defined four distinct subclasses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/57\">",
"       57",
"      </a>",
"      ]. Tumors expressing neuroendocrine-type genes had a significantly less favorable survival than those lacking such characteristics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/57\">",
"       57",
"      </a>",
"      ]. The genes that defined the neuroendocrine cluster adenocarcinomas included dopa decarboxylase, achaete-scute homolog 1, and the serine protease kallikrein 11.",
"     </li>",
"     <li>",
"      Others used GEP to predict outcome from surgery in 67 patients with resected stage I adenocarcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/56\">",
"       56",
"      </a>",
"      ]. A specific group of genes distinguished high-risk from lower risk groups, with significantly different survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/56\">",
"       56",
"      </a>",
"      ]. Among the 50 genes comprising the risk index were erbB2, VEGF, S100P, cytokeratin 7 and 18, and fas-associated death domain protein.",
"     </li>",
"     <li>",
"      In another series of 125 patients from Taiwan with surgically resected NSCLC, 16 genes were identified that correlated with increased or decreased survival. Further RT-PCR validation assay confirmed the microarray findings and showed that survival was significantly associated with five of the 16 genes (DUSP6, MMD, STAT1, ERBB3, and LCK). The five-gene signature was further validated in microarray data from patients of Western population and was an independent predictor of recurrence and overall survival for patients with surgical resection of NSCLC without any adjuvant therapy. This GEP profile is being used to select high risk patients for adjuvant chemotherapy in prospective clinical trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/58,59\">",
"       58,59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene expression profiling (GEP) by means of DNA microarrays is an evolving approach to classification, diagnosis, and prognostication of NHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/14,60-67\">",
"     14,60-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous disease in which approximately 40 percent of patients with advanced stage disease respond well to combination chemotherapy and are long-term survivors. Using GEP, DLBCL has been subclassified into three distinct molecular subgroups, germinal center B-cell-like (GCB), activated B-cell-like (ABC), and other (type 3), that appear to be derived from different stages of B-cell differentiation, utilize different oncogenic mechanisms, and differ clinically in their ability to be cured by multiagent chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/64,66\">",
"     64,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients whose tumors express genes characteristic of germinal center B cells (GCB) have a significantly better outcome from chemotherapy than those whose gene expression is more typical of activated B cells (ABC) (",
"    <a class=\"graphic graphic_figure graphicRef63638 \" href=\"mobipreview.htm?29/30/30189\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/64,66\">",
"     64,66",
"    </a>",
"    ]. In one series for example, a clustering algorithm applied to 58 patients with DLBCL receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (CHOP) chemotherapy separated patients into two groups with very different five-year overall survival rates (70 versus 12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29127?source=see_link&amp;anchor=H17219010#H17219010\">",
"     \"Prognosis of diffuse large B cell lymphoma\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most of the early studies used fresh frozen tissue sections, similar results have been reported with GEP performed on formalin-fixed, paraffin-embedded material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. No formal head-to-head comparisons of GEP from fresh versus archived materials have yet been performed.",
"   </p>",
"   <p>",
"    GEP has also been used to develop a more precise molecular diagnosis of primary mediastinal B-cell lymphoma, a clinically unfavorable entity that cannot be reliably distinguished from other types of diffuse large B-cell lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/68\">",
"     68",
"    </a>",
"    ]. These tumors do poorly with CHOP chemotherapy alone and may need more aggressive therapy than used for standard DLBCL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=see_link&amp;anchor=H22#H22\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Primary mediastinal large B cell lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, GEP has the potential to reveal new therapeutic molecular targets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/62\">",
"     62",
"    </a>",
"    ]. As an example, the ABC subtype of DLBCL is characterized by constitutive activation of the nuclear factor kappaB (NF-kappaB) signaling pathway; interference with this pathway selectively kills these lymphoma cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/65\">",
"     65",
"    </a>",
"    ]. The ubiquitin-proteasomal pathway and the NF-kappaB axis are intimately involved in the control of apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Inhibitors of this pathway (eg, proteasome inhibitors) can induce apoptosis in human leukemia cells that ectopically express the antiapoptotic protein Bcl-2. One such agent, the synthetic dipeptide boronic acid",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , is a potent promoter of apoptosis in several human tumor cell types. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Bortezomib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapidly evolving field of DNA microarray analysis and gene expression profiling has wide-ranging implications for the molecular classification of tumors, refinement of prognostic estimates, and prediction of response to therapy. Despite its exciting potential and significant recent advances, this field remains relatively new, and it is premature to conclude that microarray data can be used as a sole means of classifying cancers or predicting outcomes of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the specific challenges that must be met are the need for larger studies with appropriate validation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/72-75\">",
"     72-75",
"    </a>",
"    ], standardization of methods and establishment of guidelines for the conduct and reporting of studies (as are being worked on by the Microarray Gene Expression Data Society,",
"    <a class=\"external\" href=\"file://www.mged.org/\">",
"     www.mged.org",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/75\">",
"     75",
"    </a>",
"    ], and the formation of repositories and registries where research institutions may deposit data for comparison with independent works involving the same malignant disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/76\">",
"     76",
"    </a>",
"    ]. Finally, DNA microarray-based tests must demonstrate utility in prospectively designed clinical trials before this technology is considered a routine part of clinical evaluation. These studies may eventually establish a new treatment paradigm in personalized cancer therapy in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PROTEOMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite significant progress in the field of DNA microarrays and GEP, there are some limitations to using a genomic (nucleic acid) approach to molecular tumor classification:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proteins rather than nucleic acids represent the functional output of the cell. RNA expression is often not tightly correlated with protein expression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/77,78\">",
"       77,78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genomic analysis does not detect posttranslational changes such as proteolytic processing, phosphorylation, or glycosylation, which can alter the activity of a protein. These posttranslational modifications are often critical in various signaling pathways involved in tumorigenesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/77,79,80\">",
"       77,79,80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared to the study of DNA or RNA expression patterns, analysis of protein expression in tissues, serum, and other biologic samples (called proteomics) may provide a more accurate understanding of the molecular complexities of human tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Protein separation and quantification: 2-dimensional gel electrophoresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The central tool for proteomics analysis has been two-dimensional polyacrylamide gel electrophoresis (2D-PAGE or 2-DE), which separates solubilized proteins on the basis of charge (using a pH gradient within the gel) in the first dimension, and molecular size in the second dimension (hence the term 2-DE) (",
"    <a class=\"graphic graphic_figure graphicRef76724 \" href=\"mobipreview.htm?3/10/3235\">",
"     figure 4",
"    </a>",
"    ). Following separation, the protein spots on the gel are then visualized by a photochemical silver-based staining technique. This analytical technique can separate and display approximately 1000 proteins from complex mixtures on a single gel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/82-84\">",
"     82-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial reports of the analysis of protein expression profiles in cancer patients using 2-DE described only differences in patterns of protein expression rather than specific proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/85\">",
"     85",
"    </a>",
"    ]. Separated proteins could only be identified by comigration, specific antibody labeling, or chemical microsequencing, all of which were time-consuming and technically demanding. Because there is simple method for protein amplification, highly sensitive methodologies needed to be developed to identify low-abundance proteins that are important in the malignant process.",
"   </p>",
"   <p>",
"    Although 2-DE is a powerful tool for the study of differences in protein expression that characterize any two cell types or tissues, it is difficult to apply this technique to large numbers of clinical samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/83,86\">",
"     83,86",
"    </a>",
"    ]. The number of unique proteins contained in a tumor is higher than the number of spots detectable with 2-DE. The human genome contains as many as 40,000 genes. Even if only 3 to 5 percent are expressed at any one time (1200 to 2000 genes), the number of distinct proteins is much higher because of mRNA splicing, posttranslational modification, and proteolysis.",
"   </p>",
"   <p>",
"    In addition, many early investigations studied lysates from cell lines and human tissues to identify \"tumor-specific\" changes in protein expression. This approach is limited by the heterogeneity of human tumors, and the inclusion of stroma, normal cells, and premalignant lesions along with tumor in many samples.",
"   </p>",
"   <p>",
"    The modern era of proteomics as a method of molecular \"fingerprinting\" of human tumors was made possible by several technological advances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genomic sequencing (ie, completion of the first phase of the Human Genome Project) and the availability of publicly available databases that catalog known protein and nucleic acid sequences",
"     </li>",
"     <li>",
"      Highly sensitive quantitative techniques to detect small amounts of protein in biologic samples",
"     </li>",
"     <li>",
"      Laser capture microdissection (LCM) technology, which permits the isolation of selected cells out of a tissue section",
"     </li>",
"     <li>",
"      Technical advances in mass spectrometry (MS), allowing highly sensitive and specific protein identification both in the solubilized (liquid) state and in the solid state (ie, directly from tissue samples or sections)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these advances, 2-DE remains the foundation of most proteomics studies (particularly investigations of biomarkers in serum), because of its ability to separate relatively large proteins from biologic materials. With this simple technique and subsequent analysis of gel images with specialized software [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/87\">",
"     87",
"    </a>",
"    ], differences in protein expression (eg, presence versus absence, or intensity of different proteins or isoforms) between healthy and diseased tissues can be revealed. The proteins of interest can then be identified, typically by MS-based strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Protein identification: mass spectrometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mass spectrometer is a highly accurate instrument that can separate individual proteins of very similar molecular weight or mass. MS requires a smaller amount of material and has a higher throughput than other sequencing methods for protein identification. The goal of applying MS in clinical proteomics is to generate protein profiles (mass:charge",
"    <span class=\"nowrap\">",
"     [m/z]",
"    </span>",
"    ratio versus signal intensity) from body fluids (eg, serum, saliva, urine) or tissue samples to detect quantitative and qualitative changes in protein expression levels that correlate with the disease states.",
"   </p>",
"   <p>",
"    MS operates in the gas phase, and peptides thus must first be ionized. The development of newer, more gentle ionization methods has led to breakthroughs in the application of MS to biotechnology and clinical proteomics. Ionization can be accomplished by electrospray ionization for solubilized (liquid state) samples, or by laser desorption techniques for samples in the solid state (see below).",
"   </p>",
"   <p>",
"    The mass of the ions can then be accurately measured by various coupled analyzers, such as a \"time of flight\" analyzer. In simple terms, the MS instrument accelerates the ionized proteins across a fixed voltage potential in a high vacuum, measuring the amount of time (the \"time of flight\" or TOF) required for the ion to hit a detector. This allows the molecular weight or mass of a single positively charged molecule to be accurately measured and displayed according to their mass:charge ratio",
"    <span class=\"nowrap\">",
"     (m/z).",
"    </span>",
"   </p>",
"   <p>",
"    Proteins that are separated on 2-DE gels can be identified by cutting individual spots from the gels. The excised protein spot is digested with trypsin, cleaving proteins at specific amino acid sequences and breaking them down into a mixture of peptides. The peptide fragments produced by trypsin digestion of any protein have a unique mass that can be measured accurately with MS to produce a peptide mass \"fingerprint\".",
"   </p>",
"   <p>",
"    This protein signature or fingerprint is then compared with the peptide masses predicted from theoretical digestion of protein sequences contained within published databases such as SWISS-PROT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/88\">",
"     88",
"    </a>",
"    ], thus allowing identification of the protein from which the fragments originated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/89,90\">",
"     89,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Primary fingerprinting with MS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analyzing cellular proteins with 2-D gels is a technically challenging, time-intensive process that is difficult to automate and is not readily applicable to assessing protein alterations from hundreds of samples or the multitude of proteins that characterize a heterogeneous tumor. 2-DE fails to resolve most proteins that are larger than approximately 100 kDa or smaller than 5 kDa. Furthermore, 2-DE cannot routinely resolve complex protein mixtures into more than 1000 spots.",
"   </p>",
"   <p>",
"    Complementary technologies have been developed which apply the sensitivity and specificity of MS to rapid and direct mapping and imaging of biomolecules that are present in body fluids or tissue sections. The available techniques, SELDI-TOF MS (surface-enhanced laser desorption ionization time of flight mass spectrometry) and MALDI-TOF MS (matrix-assisted laser desorption ionization time of flight mass spectrometry), use a laser to desorb and ionize proteins from a solid surface and thus are called \"laser desorption\" techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     SELDI-TOF MS",
"    </span>",
"    &nbsp;&mdash;&nbsp;SELDI-TOF MS differs from MALDI-TOF MS mainly in the functionalization of the chips (the MALDI target) to allow selective fractionation and enrichment of",
"    <span class=\"nowrap\">",
"     peptides/proteins",
"    </span>",
"    in the clinical sample analytes. With SELDI-TOF MS, a solubilized sample is adsorbed directly onto one of several proprietary chromatographic biochip arrays made of stainless steel or aluminum-based solid surfaces or chips (ProteinChip) that have physicochemical characteristics (eg, charge or hydrophobicity) that permit the capture and fractionation of proteins from complex mixtures prior to laser desorption for MS. After a wash step, proteins and peptides of selective affinity are retained on the chip, and analyzed by a linear TOF MS technology similar to MALDI-TOF MS. Using this technique, peptide and protein profiles can be easily obtained within minutes and hundreds of proteins can be profiled simultaneously from samples of patients or a small number of cells when coupled with LCM technology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SELDI-TOF MS platform offers several advantages over 2-DE. It is able to profile proteins regardless of their intrinsic hydrophobicity (a limitation of 2-DE), and it has a high sensitivity for the detection of proteins in the 15 kDa range, a size that is problematic for 2-DE resolution. In addition, SELDI-TOF MS requires a smaller amount of sample and has a higher throughput than 2-DE.",
"   </p>",
"   <p>",
"    In early studies, SELDI MS analysis of serum proteins was capable of defining patterns that could distinguish patients with cancer from normal controls and from those with premalignant lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/93\">",
"     93",
"    </a>",
"    ]. Subsequent attempts have focused on using SELDI-TOF MS to identify discriminatory \"proteomics signatures\" of spectral peaks between normal versus malignant tissues, as well as to identify single disease-related tumor biomarkers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/94-100\">",
"     94-100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential problem is that routine identification of the protein peaks using this approach is not straightforward due to the requirement for front-end fractionation of the protein samples, and subsequent downstream purification methods. However, direct on-chip protein identification is technically possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the clinical application of proteomic patterns requires that results be reproducible in different laboratories and on multiple samples from the same patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/102\">",
"     102",
"    </a>",
"    ]. As an example, the initial positive results from sera of women with ovarian cancer and a control group could not be readily reproduced when the datasets were generated using two different protein chips [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/97,103\">",
"     97,103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     MALDI-TOF MS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to SELDI-TOF MS, MALDI-TOF MS does not require solubilization or preseparation of tissue samples. Using this technique, high resolution mass spectrograms can be obtained directly from solid phase samples (eg, in tissue sections) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/91,92,104,105\">",
"     91,92,104,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a typical procedure, a 12 micron frozen tissue section is freeze-dried onto a conductive MALDI plate, and coated with a solution of a matrix, usually a low molecular weight crystalline compound such as a cinnamic acid analog (",
"    <a class=\"graphic graphic_figure graphicRef70974 \" href=\"mobipreview.htm?41/49/42771\">",
"     figure 5",
"    </a>",
"    ). When dry, the sample is introduced into the vacuum inlet of a mass spectrometer, and then irradiated with a finely focused laser beam from a 377 nm N2 laser. The beam, which is approximately circular with a diameter of 25 microns, is directed at regions of interest in the tumor, which are selected by examining adjacent tissue sections that are processed for conventional light microscopy (hematoxylin and eosin, H&amp;E).",
"   </p>",
"   <p>",
"    Each consecutive spot produces a mass spectrum that reflects the molecules that are present within the irradiated area. For most tissue sections, over 200 protein and peptide peaks are found in the mass spectrum from each spot ablated by the laser. Application of the laser, acquisition of data, download to a computer, data processing, and repositioning of the sample stage are all automated, and the procedure is rapid.",
"   </p>",
"   <p>",
"    Samples can be obtained from well-defined regions (eg, normal tissue, malignant tissue, necrotic areas, the leading edge of a tumor), many of which have unique subsets of proteins and peptides. Images can then be created of different patterns of protein expression by integrating the peak areas and plotting the relative values using a color scale (",
"    <a class=\"graphic graphic_figure graphicRef79121 \" href=\"mobipreview.htm?25/30/26094\">",
"     figure 6",
"    </a>",
"    ). Proteins can also be identified through extraction, fractionation, proteolysis, MS sequencing of one or more of the fragments, and protein database searching.",
"   </p>",
"   <p>",
"    The ClinProt&reg; system is another integrated method for serum profiling that utilizes magnetic beads (MB) and AnchorChip&reg; technology for front-end sample fractionation and preparation prior to MS analysis. MALDI-TOF MS is used to generate protein profiles in both linear and reflector modes, with subsequent MALDI-TOF MS to identify low molecular weight serum peptides in the protein profile with high spectral resolution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A particular advantage of this platform is its ability to allow profiling to discovery of proteomic fingerprint and",
"    <span class=\"nowrap\">",
"     peptide/protein",
"    </span>",
"    identification all in a single, integrated system with high throughput. MB-based sample fractionation can be easily automated and scaled up for subsequent biomarker purification. High performance ultraflex",
"    <span class=\"nowrap\">",
"     MALDI-TOF/TOF",
"    </span>",
"    can be used to identify peptides directly from serum profiles using the same sample spot",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    re-spot the same sample.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Clinical applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The result of a proteomics analysis is the correlation of changes in protein expression with a given phenotype. Once a protein or biomarker \"signature profile\" has been identified, results must be validated in independent, large study sets. This requires high throughput technology, permitting the analysis of hundreds of cancer tissue samples at a time.",
"   </p>",
"   <p>",
"    The identified proteins may represent important biomarkers for early diagnosis, yield valuable information about the disease process and thus identify targets for novel therapeutic intervention, or provide surrogate markers for therapeutic efficacy or treatment-related toxicity.",
"   </p>",
"   <p>",
"    The following illustrate clinical areas where proteomics may have potential clinical utility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Non-small cell lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary data suggest that MALDI-TOF MS analysis of protein expression profiles from frozen sections of human surgically resected lung tumors permits the separation of tumors according to histologic type, providing potentially useful prognostic information in patients with resected non-small cell lung cancer (NSCLC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/91,107,108\">",
"     91,107,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report, protein spectra were obtained from 79 lung tumors and 14 normal lung tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/107\">",
"     107",
"    </a>",
"    ]. A model was established using 42 lung tumors and eight normal samples, which was then validated on a blinded test cohort of 37 lung tumors and six normal lung samples. Using this approach over 1000 distinct protein species could be analyzed from less than one nanogram of each tissue sample.",
"   </p>",
"   <p>",
"    Representative examples of MS spectra from adenocarcinoma, squamous cell, and normal lung are shown in the following figure (",
"    <a class=\"graphic graphic_figure graphicRef62162 \" href=\"mobipreview.htm?42/24/43392\">",
"     figure 7",
"    </a>",
"    ). The protein spectra of lung cancers and normal lung are different; peaks are higher in the tumor samples than in normal lung, and clearly distinguishable from background noise. A discriminatory pattern of protein expression was also evident when the adenocarcinoma and squamous cell carcinoma were compared (",
"    <a class=\"graphic graphic_figure graphicRef62162 \" href=\"mobipreview.htm?42/24/43392\">",
"     figure 7",
"    </a>",
"    ), and when lung primary tumors were compared to pulmonary metastasis.",
"   </p>",
"   <p>",
"    These proteomics results may have prognostic value as well. When the protein spectra of 66 patients with resected NSCLC were analyzed, a single pattern comprised of 15 distinct MS peaks could distinguish between patients with good or poor prognoses (median survival 33 versus 6 months, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/107\">",
"     107",
"    </a>",
"    ]. This association was present even after adjustment for stage and histologic grade.",
"   </p>",
"   <p>",
"    Other data suggest that serum protein profiling may be useful in the early diagnosis of aerodigestive tumors (lung, head and neck cancer) in subjects who are at high risk (eg, smokers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/109\">",
"     109",
"    </a>",
"    ]. The spectral profile derived from the sera of patients with cancer was significantly different from the sera of control subjects. If these results are confirmed by others, a proteomics-based analysis may be useful as a screening test for these cancers.",
"   </p>",
"   <p>",
"    There have been considerable efforts in recent years in developing serum-based proteomics classifier to predict survival and treatment benefits in NSCLC. A commercially available serum proteomic MALDI-TOF based classifier (VeriStrat) was adopted for stratifying and predicting survival after treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    in a blinded fashion to pretreatment sera from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . VeriStrat was found to be able to classify these patients into two significantly different outcome groups that had &ldquo;better&rdquo; and &ldquo;worse&rdquo; outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/110\">",
"     110",
"    </a>",
"    ]. In another study, the VeriStrat classification was used in 137 patients enrolled in the ECOG 3503 (single-arm phase II study of erlotinib in first-line advanced lung cancer) to analyze their pretreatment serum proteomics, and identified 64 of 88 (73 percent) as predicted to have &ldquo;good&rdquo; and 24 of 88 (27 percent) predicted to have &ldquo;poor&rdquo; outcomes. A statistically significant correlation of VeriStrat status (p&lt;0.001) was found with survival, as in the case of EGFR mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/111\">",
"     111",
"    </a>",
"    ]. Current effort continues to be focused on developing the VeriStrat platform as predictive biomarker for targeted therapy response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lack of specificity of serum PSA for discriminating between prostate cancer and benign prostatic hyperplasia (BPH) limits its utility for early diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link&amp;anchor=H3#H3\">",
"     \"Screening for prostate cancer\", section on 'Measuring PSA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several reports suggest that serum proteomics may provide a better biomarker for early detection of prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/94,95,100,112\">",
"     94,95,100,112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first series used a serum SELDI MS to analyze serum proteins and differentiate prostate cancer from BPH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/94\">",
"       94",
"      </a>",
"      ]. Serum protein profiles from 326 men with prostate cancer, BPH, or unaffected controls were used to develop a decision tree classification algorithm, which correctly classified 96 percent of the samples. In a subsequent blinded validation set, this approach had a sensitivity of 83 percent and a specificity of 97 percent.",
"     </li>",
"     <li>",
"      Using a different approach, serum was analyzed for the presence of autoantibodies directed against tumor-specific antigens in patients with prostatic cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/112\">",
"       112",
"      </a>",
"      ]. Serum samples were analyzed from 39 patients and 21 controls to establish a panel of 22 markers. An algorithm was then developed in a training phase involving 129 samples, and validated in samples from an additional 128 patients. Results were superior to those with PSA in this population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the results from approaches such as these are reproducible in larger studies and if they are superior to PSA in a screening population as opposed to patients with biopsy proven disease, serum proteomics may be useful either as a screening tool or in deciding whether to perform a biopsy in a man with an elevated serum PSA level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Adult acute lymphoblastic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of peripheral blood from 57 adults with a confirmed diagnosis of acute lymphoblastic leukemia, use of a decision tree based on proteomics provided positive prediction of recurrence 84 to 92 percent of the time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/113\">",
"     113",
"    </a>",
"    ]. Recurrence prediction was independent of cytogenetics, marrow blast count, serum level of lactate dehydrogenase, beta-2 microglobulin levels, or surface marker studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5280328\">",
"    <span class=\"h1\">",
"     MICRORNA PROFILING",
"    </span>",
"    &nbsp;&mdash;&nbsp;MicroRNAs (miRNAs) are a novel class of endogenous small (18 to 24 nucleotides long) noncoding single-stranded RNAs that regulate gene expression at the posttranscriptional level. Evolutionarily conserved, miRNAs bind to the 3&rsquo; untranslated regions of messenger RNAs (mRNAs), and induce degradation or inhibition of protein translation. &nbsp;",
"   </p>",
"   <p>",
"    MiRNAs possess many critical regulatory functions in a wide range of biological processes such as cell proliferation, differentiation, survival and apoptosis, and stress response. The miRBase miRNA registry now includes over 1000 human miRNAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/114\">",
"     114",
"    </a>",
"    ]. Any one particular miRNA has the potential to modulate the expression and functions of hundreds of downstream target genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/115\">",
"     115",
"    </a>",
"    ]. In addition, the existence of feedback regulation mechanisms between miRNA, its targets, and their products allows for amplification or inhibition of a specific signal. Hence, alteration of even a handful of miRNAs can possibly result in dramatic deregulation of physiologic cellular functions. &nbsp;",
"   </p>",
"   <p>",
"    Human miRNA genes are frequently located at fragile sites and genomic regions involved in cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/116\">",
"     116",
"    </a>",
"    ]. MiRNA expression is deregulated widely in solid tumors and hematologic malignancies, and miRNAs have been implicated both in the initiation and progression of human cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/117\">",
"     117",
"    </a>",
"    ]. MiRNAs appear to have a dual role in carcinogenesis by serving both as oncogenes (termed oncomirs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/118\">",
"     118",
"    </a>",
"    ]) and tumor suppressors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following sections will provide a few examples of early data on miRNA profiling for cancer diagnosis and prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5280353\">",
"    <span class=\"h2\">",
"     Leukemia/lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients diagnosed with B-cell chronic lymphocytic leukemia (CLL), investigators have found deletions or downregulation of two clusters of miRNA genes, miR-15a and miR-16-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/120\">",
"     120",
"    </a>",
"    ]. These results provided the first evidence of a miRNA serving as a tumor suppressor in a human cancer. Both miR-15a and miR-16-1 have been shown to target the anti-apoptotic protein BCL-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/121\">",
"     121",
"    </a>",
"    ], and its deregulation (mutation or deletion) appears relevant to the development of indolent rather than aggressive CLL. Other miRNAs may be involved as well. In one large study, a 13-miRNA signature was identified that could distinguish between indolent and aggressive CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/122\">",
"     122",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42361?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathophysiology and genetic features of chronic lymphocytic leukemia\", section on 'MicroRNA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MiRNA profiles with a unique association to acute myelogenous leukemia (AML) subgroups have been reported, which also appear to have prognostic significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/123\">",
"     123",
"    </a>",
"    ]. The impact of miRNAs on AML pathogenesis is not yet understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/124\">",
"     124",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link&amp;anchor=H24780405#H24780405\">",
"     \"Molecular genetics of acute myeloid leukemia\", section on 'Mutations affecting DNA methylation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link&amp;anchor=H17#H17\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'MicroRNA expression profiling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MiRNAs may also be important in lymphomas. MiR-155 is upregulated in diffuse large B-cell lymphoma, Burkitt&rsquo;s lymphoma, and Hodgkin&rsquo;s lymphomas, suggesting it may function as an oncogene. In a transgenic mouse model, a B-cell malignancy ultimately developed in mice with constitutive miR-155 overexpression in B-lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5280361\">",
"    <span class=\"h2\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional studies on one of these miRNAs, let-7, indicate that it regulates the oncogene RAS and the HMGA2 (high mobility group at-hook 2) gene directly in patients with lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/126,127\">",
"     126,127",
"    </a>",
"    ]. These data suggest a potential pathogenetic role in the disease.",
"   </p>",
"   <p>",
"    MiRNA profiling for classification and prognostication in lung cancer is an active area of investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/128-132\">",
"     128-132",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MiRNA expression profiles correlate with survival of lung adenocarcinomas, including those classified as stage I [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/128,133\">",
"       128,133",
"      </a>",
"      ]. A potential prognostic role for miRNA expression was also suggested in a study that evaluated the expression of a panel of 752 miRNAs in 77 cases of stage I non-small cell lung cancer (NSCLC), 37 of which recurred and 40 did not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/134\">",
"       134",
"      </a>",
"      ]. Differential expression between the two groups was present for 49 percent of the miRNAs studied.",
"     </li>",
"     <li>",
"      MiRNA studies have also been applied to the diagnostic distinction between squamous and non-squamous NSCLC subtypes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/135\">",
"       135",
"      </a>",
"      ]. This work has potential clinical relevance given that recent advances in treatment of lung cancer require greater accuracy in the subclassification of NSCLC (eg, use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      in combination with chemotherapy for patients with non-squamous histology NSCLC). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H525779160#H525779160\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Chemotherapy plus bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5280368\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relevance of miRNA activity in breast cancer biology and behavior is supported by the evidence that miRNAs participate in the modulation of two of the most important molecules in breast cancer, estrogen receptor and HER2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/136-140\">",
"     136-140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have described an association between miRNA profiles and pathologic and clinical features of breast cancer, as well as prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/136\">",
"     136",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MiRNAs are differentially expressed in specific molecular subgroups of breast cancer (eg, luminal A versus basal-like [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/141\">",
"       141",
"      </a>",
"      ]) and in certain histologic subtypes (eg, inflammatory versus noninflammatory breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/142\">",
"       142",
"      </a>",
"      ]). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41302?source=see_link\">",
"       \"Molecular intrinsic subtypes of breast cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10103?source=see_link\">",
"       \"Inflammatory breast cancer: Pathology and molecular pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In two studies, miR-21 was found overexpressed with a key oncogenic role in promoting tumor cell survival and proliferation; overexpression correlated with advanced stage disease and poor prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/143,144\">",
"       143,144",
"      </a>",
"      ]. In addition, a regulatory role for miRNA-10b has been proposed for mediating breast cancer invasion and metastasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/145,146\">",
"       145,146",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13403558\">",
"    <span class=\"h2\">",
"     Role in prognostication",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increasing amount of data support a role for microRNAs in clinical outcome prediction for a wide variety of cancers. A systematic review and meta-analysis&nbsp;of 43 studies pertaining to 20 different tumor types concluded that the miRNAs most frequently associated with poor outcomes after accounting for differences in miRNA assessment due to platform type were let-7 (decreased expression) and miRNA 21 (increased expression) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/147\">",
"     147",
"    </a>",
"    ]. The analysis adjusted for how many&nbsp;times each miRNA was assayed, as not all known miRNAs were assessed upfront in all included studies.",
"   </p>",
"   <p>",
"    Several miR classifiers were associated with prognosis above and beyond traditional clinical and prognostic metrics for a diverse group of human malignancies. Moreover, the finding of specific miRNA species (ie, let-7 and miR-21) that were associated with survival outcome and consistently&nbsp;identified across diverse studies in&nbsp;different cancers suggests that some miR-coordinated regulatory pathways are common to many cancers.&nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5280375\">",
"    <span class=\"h2\">",
"     Role in cancer therapeutics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discovery of miRNAs functioning as potential oncogenes and tumor suppressor genes in cancer has generated interested in their use as targets for cancer therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/148,149\">",
"     148,149",
"    </a>",
"    ]. In addition, MiRNA might also have treatment modulating effects in human cancer, and potential as anticancer therapeutic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/47/39674/abstract/149-151\">",
"     149-151",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5280382\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emerging evidence suggests a role for deregulation of microRNA (miRNA) expression in tumorigenesis, with potential applications in cancer diagnostics, classification, prognostication, and possibly treatment. This field is in its infancy and further work will be needed to validate any clinical applications for the use of miRNA in human cancer care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with cancer, clinical management decisions and prognostic estimates are often based solely upon histopathologic analysis of tumor tissue. However, tumor behavior is often inadequately explained by histology alone. The examination of multiple expressed genes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proteins may provide more useful information for both classification and prognostication of individual tumors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DNA microarray analysis can simultaneously measure the expression level of thousands of genes. Expression levels of each gene can then be compared across many tissue or tumor samples. In this way, groups or clusters of genes can be identified whose expression varies in similar ways. Gene expression profiling (GEP) is a powerful tool to identify genes and pathways that are aberrantly expressed during carcinogenesis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'GEP and DNA microarray analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rapidly evolving field of DNA microarray analysis and GEP has wide-ranging implications for the molecular classification of tumors, refinement of prognostic estimates, and prediction of response to therapy. GEP can also suggest novel therapeutic targets. However, despite its exciting potential and significant recent advances, this field remains relatively new, and it is premature to conclude that microarray data can be used as a sole means of classifying cancers or predicting outcomes of treatment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical applications of DNA microarrays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The application of clinical proteomics to clinical oncology has accelerated tremendously with rapid advances in mass spectrometry (MS) technology. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Proteomics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      These advances may be useful in several dimensions (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Clinical applications'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Proteomics research will enhance our understanding of tumor biology, particularly the aberrant cellular signaling that characterizes malignant disease.",
"     </li>",
"     <li>",
"      Rapid advances in MS platforms coupled with high throughput and automation capacity will facilitate identification of potential novel biomarkers.",
"     </li>",
"     <li>",
"      Identification of complex disease-specific biomarker patterns may allow both better sensitivity and specificity when compared to individual single biomarker analysis, as is used currently for several cancers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite the exciting potential for clinical proteomics, substantial challenges remain, particularly with regard to standardization, validation, and reproducibility of results. Predictive proteomic biomarkers ultimately need to be tested in prospective therapeutics clinical trials to be fully validated.",
"     </li>",
"     <li>",
"      MicroRNAs (miRNAs) are a novel class of small (approximately 22 nucleotides long) noncoding single-stranded RNAs that regulate gene expression at the posttranscriptional level. Emerging evidence suggests a role for deregulation of miRNA expression in tumorigenesis, with potential applications in cancer diagnostics, classification, prognostication, and possibly treatment. This field is in its infancy and further work will be needed to validate any clinical applications for the use of miRNA in human cancer care. (See",
"      <a class=\"local\" href=\"#H5280328\">",
"       'MicroRNA profiling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/1\">",
"      Mariadason JM, Augenlicht LH, Arango D. Microarray analysis in the clinical management of cancer. Hematol Oncol Clin North Am 2003; 17:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/2\">",
"      Tefferi A, Bolander ME, Ansell SM, et al. Primer on medical genomics. Part III: Microarray experiments and data analysis. Mayo Clin Proc 2002; 77:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/3\">",
"      Garnis C, Lockwood WW, Vucic E, et al. High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 2006; 118:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/4\">",
"      Wittes J, Friedman HP. Searching for evidence of altered gene expression: a comment on statistical analysis of microarray data. J Natl Cancer Inst 1999; 91:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/5\">",
"      Baggerly KA, Coombes KR, Hess KR, et al. Identifying differentially expressed genes in cDNA microarray experiments. J Comput Biol 2001; 8:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/6\">",
"      Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998; 95:14863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/7\">",
"      Simon R. Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Br J Cancer 2003; 89:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/8\">",
"      Ramaswamy S, Tamayo P, Rifkin R, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 2001; 98:15149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/9\">",
"      Hwang D, Schmitt WA, Stephanopoulos G, Stephanopoulos G. Determination of minimum sample size and discriminatory expression patterns in microarray data. Bioinformatics 2002; 18:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/10\">",
"      Mukherjee S, Tamayo P, Rogers S, et al. Estimating dataset size requirements for classifying DNA microarray data. J Comput Biol 2003; 10:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/11\">",
"      Ben-Dor A, Bruhn L, Friedman N, et al. Tissue classification with gene expression profiles. J Comput Biol 2000; 7:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/12\">",
"      Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002; 99:6567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/13\">",
"      Khan J, Wei JS, Ringn&eacute;r M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001; 7:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/14\">",
"      Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/15\">",
"      Brown MP, Grundy WN, Lin D, et al. Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci U S A 2000; 97:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/16\">",
"      Pusztai L, Ayers M, Stec J, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 2003; 9:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/17\">",
"      Gruvberger S, Ringn&eacute;r M, Chen Y, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001; 61:5979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/18\">",
"      Perou CM, S&oslash;rlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/19\">",
"      Haferlach T, Kohlmann A, Bacher U, et al. Gene expression profiling for the diagnosis of acute leukaemia. Br J Cancer 2007; 96:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/20\">",
"      Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/21\">",
"      Bullinger L, D&ouml;hner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/22\">",
"      Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/23\">",
"      Stegmaier K, Ross KN, Colavito SA, et al. Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet 2004; 36:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/24\">",
"      Leupin N, Kuhn A, H&uuml;gli B, et al. Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines. Br J Haematol 2006; 135:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/25\">",
"      Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/26\">",
"      Latil A, Bi&egrave;che I, Ch&ecirc;ne L, et al. Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. Clin Cancer Res 2003; 9:5477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/27\">",
"      Stephan C, Yousef GM, Scorilas A, et al. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol 2004; 171:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/28\">",
"      Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004; 101:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/29\">",
"      LaTulippe E, Satagopan J, Smith A, et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002; 62:4499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/30\">",
"      Yu YP, Landsittel D, Jing L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22:2790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/31\">",
"      Saha S, Bardelli A, Buckhaults P, et al. A phosphatase associated with metastasis of colorectal cancer. Science 2001; 294:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/32\">",
"      Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/33\">",
"      Watanabe T, Kobunai T, Sakamoto E, et al. Gene expression signature for recurrence in stage III colorectal cancers. Cancer 2009; 115:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/34\">",
"      Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003; 100:10393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/35\">",
"      S&oslash;rlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/36\">",
"      Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100:8418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/37\">",
"      Thuerigen O, Schneeweiss A, Toedt G, et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006; 24:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/38\">",
"      Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004; 22:2284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/39\">",
"      Iwao-Koizumi K, Matoba R, Ueno N, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005; 23:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/40\">",
"      Jansen MP, Foekens JA, van Staveren IL, et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005; 23:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/41\">",
"      Hannemann J, Oosterkamp HM, Bosch CA, et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005; 23:3331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/42\">",
"      Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11:5678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/43\">",
"      Chang JC, Wooten EC, Tsimelzon A, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005; 23:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/44\">",
"      Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006; 24:4236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/45\">",
"      Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/46\">",
"      Pusztai L, Ayers M, Stec J, Hortob&aacute;gyi GN. Clinical application of cDNA microarrays in oncology. Oncologist 2003; 8:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/47\">",
"      Glinsky GV, Higashiyama T, Glinskii AB. Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm. Clin Cancer Res 2004; 10:2272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/48\">",
"      van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/49\">",
"      van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/50\">",
"      Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/51\">",
"      Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/52\">",
"      Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/53\">",
"      Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001; 98:13784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/54\">",
"      Yamagata N, Shyr Y, Yanagisawa K, et al. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res 2003; 9:4695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/55\">",
"      Jones MH, Virtanen C, Honjoh D, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004; 363:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/56\">",
"      Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/57\">",
"      Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001; 98:13790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/58\">",
"      Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007; 356:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/59\">",
"      Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006; 355:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/60\">",
"      Rimsza LM, Leblanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008; 112:3425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/61\">",
"      Malumbres R, Chen J, Tibshirani R, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 2008; 111:5509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/62\">",
"      Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003; 348:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/63\">",
"      Thieblemont C, Nasser V, Felman P, et al. Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 2004; 103:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/64\">",
"      Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/65\">",
"      Wiestner A, Staudt LM. Towards molecular diagnosis and targeted therapy of lymphoid malignancies. Semin Hematol 2003; 40:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/66\">",
"      Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/67\">",
"      Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/68\">",
"      Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/69\">",
"      Goldberg AL, Rock K. Not just research tools--proteasome inhibitors offer therapeutic promise. Nat Med 2002; 8:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/70\">",
"      Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9:6316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/71\">",
"      Winegarden N. Microarrays in cancer: moving from hype to clinical reality. Lancet 2003; 362:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/72\">",
"      Ntzani EE, Ioannidis JP. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 2003; 362:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/73\">",
"      Dobbin KK, Beer DG, Meyerson M, et al. Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res 2005; 11:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/74\">",
"      Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/75\">",
"      Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007; 99:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/76\">",
"      Stoeckert CJ Jr, Causton HC, Ball CA. Microarray databases: standards and ontologies. Nat Genet 2002; 32 Suppl:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/77\">",
"      Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997; 18:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/78\">",
"      Tew KD, Monks A, Barone L, et al. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. Mol Pharmacol 1996; 50:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/79\">",
"      Wilkins MR, Sanchez JC, Williams KL, Hochstrasser DF. Current challenges and future applications for protein maps and post-translational vector maps in proteome projects. Electrophoresis 1996; 17:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/80\">",
"      Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002; 1:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/81\">",
"      Bichsel VE, Liotta LA, Petricoin EF 3rd. Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J 2001; 7:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/82\">",
"      Corthals GL, Wasinger VC, Hochstrasser DF, Sanchez JC. The dynamic range of protein expression: a challenge for proteomic research. Electrophoresis 2000; 21:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/83\">",
"      Banks RE, Dunn MJ, Hochstrasser DF, et al. Proteomics: new perspectives, new biomedical opportunities. Lancet 2000; 356:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/84\">",
"      Cristea IM, Gaskell SJ, Whetton AD. Proteomics techniques and their application to hematology. Blood 2004; 103:3624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/85\">",
"      Wright GL Jr. Two-dimensional acrylamide gel electrophoresis of cancer-patient serum proteins. Ann Clin Lab Sci 1974; 4:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/86\">",
"      Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000; 405:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/87\">",
"      Appel RD, Palagi PM, Walther D, et al. Melanie II--a third-generation software package for analysis of two-dimensional electrophoresis images: I. Features and user interface. Electrophoresis 1997; 18:2724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/88\">",
"      Bairoch A, Apweiler R. The SWISS-PROT protein sequence data bank and its supplement TrEMBL in 1998. Nucleic Acids Res 1998; 26:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/89\">",
"      Wilm M, Shevchenko A, Houthaeve T, et al. Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry. Nature 1996; 379:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/90\">",
"      Gygi SP, Rist B, Gerber SA, et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999; 17:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/91\">",
"      Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem 1997; 69:4751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/92\">",
"      Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 2001; 7:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/93\">",
"      Paweletz CP, Gillespie JW, Ornstein DK, et al. Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Dev Res 2000; 49:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/94\">",
"      Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62:3609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/95\">",
"      Petricoin EF 3rd, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/96\">",
"      Mathelin C, Cromer A, Wendling C, et al. Serum biomarkers for detection of breast cancers: A prospective study. Breast Cancer Res Treat 2006; 96:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/97\">",
"      Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/98\">",
"      Poon TC, Yip TT, Chan AT, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003; 49:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/99\">",
"      Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004; 10:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/100\">",
"      Ornstein DK, Rayford W, Fusaro VA, et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol 2004; 172:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/101\">",
"      Caputo E, Moharram R, Martin BM. Methods for on-chip protein analysis. Anal Biochem 2003; 321:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/102\">",
"      Robbins RJ, Villanueva J, Tempst P. Distilling cancer biomarkers from the serum peptidome: high technology reading of tea leaves or an insight to clinical systems biology? J Clin Oncol 2005; 23:4835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/103\">",
"      Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004; 20:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/104\">",
"      Chaurand P, DaGue BB, Pearsall RS, et al. Profiling proteins from azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser desorption/ionization mass spectrometry. Proteomics 2001; 1:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/105\">",
"      Chaurand P, Schwartz SA, Caprioli RM. Imaging mass spectrometry: a new tool to investigate the spatial organization of peptides and proteins in mammalian tissue sections. Curr Opin Chem Biol 2002; 6:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/106\">",
"      Pusch W, Flocco MT, Leung SM, et al. Mass spectrometry-based clinical proteomics. Pharmacogenomics 2003; 4:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/107\">",
"      Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003; 362:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/108\">",
"      Chen G, Gharib TG, Wang H, et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A 2003; 100:13537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/109\">",
"      Sidransky D, Irizarry R, Califano JA, et al. Serum protein MALDI profiling to distinguish upper aerodigestive tract cancer patients from control subjects. J Natl Cancer Inst 2003; 95:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/110\">",
"      Carbone DP, Salmon JS, Billheimer D, et al. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2010; 69:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/111\">",
"      Amann JM, Lee JW, Roder H, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 2010; 5:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/112\">",
"      Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/113\">",
"      Albitar M, Potts SJ, Giles FJ, et al. Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia. Cancer 2006; 106:1587.",
"     </a>",
"    </li>",
"    <li>",
"     MicroRNA database available online at file://www.mirbase.org/ (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/115\">",
"      Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/116\">",
"      Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004; 101:2999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/117\">",
"      Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol 2011; 38:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/118\">",
"      Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/119\">",
"      Cheng CJ, Slack FJ. The Duality of OncomiR Addiction in the Maintenance and Treatment of Cancer. Cancer J 2012; 18:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/120\">",
"      Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99:15524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/121\">",
"      Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005; 102:13944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/122\">",
"      Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/123\">",
"      Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111:3183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/124\">",
"      Garzon R, Heaphy CE, Havelange V, et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009; 114:5331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/125\">",
"      Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 2006; 103:7024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/126\">",
"      Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/127\">",
"      Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007; 21:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/128\">",
"      Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/129\">",
"      Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008; 13:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/130\">",
"      Raponi M, Dossey L, Jatkoe T, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009; 69:5776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/131\">",
"      Fanini F, Vannini I, Amadori D, Fabbri M. Clinical implications of microRNAs in lung cancer. Semin Oncol 2011; 38:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/132\">",
"      Boeri M, Pastorino U, Sozzi G. Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J 2012; 18:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/133\">",
"      Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64:3753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/134\">",
"      Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010; 70:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/135\">",
"      Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009; 27:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/136\">",
"      Casta&ntilde;eda CA, Agullo-Ortu&ntilde;o MT, Fresno Vara JA, et al. Implication of miRNA in the diagnosis and treatment of breast cancer. Expert Rev Anticancer Ther 2011; 11:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/137\">",
"      Scott GK, Goga A, Bhaumik D, et al. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/138\">",
"      Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 2007; 21:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/139\">",
"      Ferracin M, Querzoli P, Calin GA, Negrini M. MicroRNAs: toward the clinic for breast cancer patients. Semin Oncol 2011; 38:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/140\">",
"      Lowery AJ, Miller N, Devaney A, et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009; 11:R27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/141\">",
"      Blenkiron C, Goldstein LD, Thorne NP, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007; 8:R214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/142\">",
"      Van der Auwera I, Limame R, van Dam P, et al. Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer 2010; 103:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/143\">",
"      Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/144\">",
"      Qian B, Katsaros D, Lu L, et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat 2009; 117:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/145\">",
"      Steeg PS. Cancer: micromanagement of metastasis. Nature 2007; 449:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/146\">",
"      Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/147\">",
"      Nair VS, Maeda LS, Ioannidis JP. Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst 2012; 104:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/148\">",
"      Sandhu S, Garzon R. Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. Semin Oncol 2011; 38:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/149\">",
"      Thorsen SB, Obad S, Jensen NF, et al. The therapeutic potential of microRNAs in cancer. Cancer J 2012; 18:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/150\">",
"      Weidhaas JB, Babar I, Nallur SM, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007; 67:11111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/47/39674/abstract/151\">",
"      Trang P, Medina PP, Wiggins JF, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010; 29:1580.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2821 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39674=[""].join("\n");
var outline_f38_47_39674=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GEP AND DNA MICROARRAY ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preparation of the microarray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Target preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hybridization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Data acquisition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - cDNA microarrays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Oligo arrays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Data analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Selecting genes of interest",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Unsupervised clustering",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Supervised clustering",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL APPLICATIONS OF DNA MICROARRAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Colon cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Lung carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PROTEOMICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Protein separation and quantification: 2-dimensional gel electrophoresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Protein identification: mass spectrometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Primary fingerprinting with MS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - SELDI-TOF MS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - MALDI-TOF MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Adult acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5280328\">",
"      MICRORNA PROFILING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5280353\">",
"      Leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5280361\">",
"      Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5280368\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13403558\">",
"      Role in prognostication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5280375\">",
"      Role in cancer therapeutics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5280382\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2821\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2821|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/36/26183\" title=\"figure 1\">",
"      Gene expr profile AML ALL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/2/18471\" title=\"figure 2\">",
"      GEP dendrogram NSCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/30/30189\" title=\"figure 3\">",
"      Survival DLBCL gene profiling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/10/3235\" title=\"figure 4\">",
"      Polyacryl gel electrophoresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/49/42771\" title=\"figure 5\">",
"      MALDI TOF methodology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/30/26094\" title=\"figure 6\">",
"      MALDI-TOF MS human lung tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/24/43392\" title=\"figure 7\">",
"      MALDI-TOF MS normal and CA lung",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10103?source=related_link\">",
"      Inflammatory breast cancer: Pathology and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=related_link\">",
"      Molecular genetics of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41302?source=related_link\">",
"      Molecular intrinsic subtypes of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42361?source=related_link\">",
"      Pathophysiology and genetic features of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=related_link\">",
"      Prognosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29127?source=related_link\">",
"      Prognosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6503?source=related_link\">",
"      Prognostic molecular profiles of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_47_39675="Criteria for a screening test";
var content_f38_47_39675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for deciding whether a screening test should be performed",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"1\">",
"        1. How great is the burden of suffering caused by the condition in terms of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discomfort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dissatisfaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Destitution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"1\">",
"        2. How good is the screening test, if one is to be performed, in terms of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Specificity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Simplicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Labeling effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cost",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Safety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acceptability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"1\">",
"        3. Are there interventions if the condition is diagnosed?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Efficacy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Patient compliance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Early treatment being more effective than later treatment",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Fletcher, RF, Fletcher, SW, Wagner, EH. Clinical Epidemiology: The Essentials, 3rd Ed, Williams &amp; Wilkins, Baltimore 1996, p. 165.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39675=[""].join("\n");
var outline_f38_47_39675=null;
var title_f38_47_39676="Rx HACEK endocarditis";
var content_f38_47_39676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested regimens for therapy of native valve endocarditis due to HACEK* microorganism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       American Heart Association",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       British Society for Antimicrobial Chemotherapy",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       European Society of Cardiology",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Adult (for patients with normal renal function)",
"      </td>",
"      <td class=\"subtitle2\">",
"       Pediatric (not to exceed dose of normal adult)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        <strong>",
"         One of the following:",
"        </strong>",
"       </p>",
"       <p>",
"        Ceftriaxone&bull; 2 g per 24 h IV or IM in 1 dose for 4 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Ampicillin-sulbactam 12 g per 24 h IV in 4 equally divided doses for 4 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Ciprofloxacin&sect; 1000 mg per 24 h PO or 800 mg per 24 h IV in 2 equally divided doses for 4 wks",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         One of the following:",
"        </strong>",
"       </p>",
"       <p>",
"        Ceftriaxone&bull; 100 mg/kg per 24 h IV or IM in 1 dose for 4 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Ampicillin-sulbactam 300 mg/kg per 24 h IV in 4 equally divided doses doses for 4 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Ciprofloxacin&sect; 20-30 mg/kg per 24 h IV or PO in 2 equally divided doses for 4 wks",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Either",
"        </strong>",
"       </p>",
"       <p>",
"        Ampicillin&Delta; 2 g IV every 4 to 6 h for 4 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Ceftriaxone&bull; 2 to 4 g per 24 h IV or IM in 1 dose for 4 wks",
"       </p>",
"       <p>",
"        <strong>",
"         plus",
"        </strong>",
"       </p>",
"       <p>",
"        Gentamicin&loz; 1 mg/kg IV every 8 to 12 h for 2 wks",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         One of the following:",
"        </strong>",
"       </p>",
"       <p>",
"        Ceftriaxone&bull; 2 g per 24 h IV or IM in 1 dose for 4 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Combination therapy with: ampicillin&Delta; 12 g per 24 h IV in 4 or 6 equally divided doses",
"        <strong>",
"         plus",
"        </strong>",
"        gentamicin&loz; 3 mg/kg per 24 h IV or IM in 2 or 3 equally divided doses for 4 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Ciprofloxacin&sect; 1000 mg per 24 h PO or 800 mg per 24 h IV in 2 equally divided doses for 4 wks",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenously; IM: intramuscularly; PO: orally; h: hours; wks: weeks",
"     <br>",
"      * Haemophilus parainfluenzae, Haemophilus aphrophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae.",
"      <br>",
"       &bull; Cefotaxime or another third- or fourth-generation cephalosporin may be substituted.",
"       <br>",
"        &Delta; If susceptibility to ampicillin has been demonstrated.",
"        <br>",
"         &loz; Gentamicin dosage adjusted for peak serum concentration of 3-4 &micro;/mL, trough &lt;1 &micro;/mL.",
"         <br>",
"          &sect; Fluoroquinolone therapy recommended only for patients unable to tolerate cephalosporin and ampicillin therapy; levofloxacin, or moxifloxacin may be substituted. Use with caution in patients &lt;18 years old.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Circulation 2005;111:3167; J Antimicrob Chemother 2004;54:971; Eur Heart J 2009;30:2369.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39676=[""].join("\n");
var outline_f38_47_39676=null;
var title_f38_47_39677="Bone markers risk hip fracture";
var content_f38_47_39677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interaction of low bone mineral density and increased bone turnover in predicting fracture risk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 282px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In women over age 75 years followed prospectively, the odds ratio for hip fracture was increased 2.7-fold in those with a 1 standard deviation reduction in hip bone mineral density (BMD) but normal markers for bone turnover (first column), approximately twofold in those with normal BMD but a value for urinary C-terminal collagen crosslink excretion (CTX) or free deoxypyridinoline excretion (D/Pyr) above the premenopausal range (second and third columns), and 4.5-fold when both risk factors were present (last two columns).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11:1531.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39677=[""].join("\n");
var outline_f38_47_39677=null;
var title_f38_47_39678="Velpeau xray technique";
var content_f38_47_39678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F71805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F71805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Velpeau view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 213px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient's arm is held in internal rotation and the film is taken superior to inferior with the patient leaning backward.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39678=[""].join("\n");
var outline_f38_47_39678=null;
var title_f38_47_39679="SEER fast stats results";
var content_f38_47_39679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Age-specific (crude) SEER incidence rates by 'expanded' race for prostate cancer, males SEER 17 registries for 2000-2003",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 382px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Statistics for American Indians/Alaska Natives do not include cases for the 2003 diagnosis year.",
"    </div>",
"    <div class=\"reference\">",
"     Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 17 Regs Public-Use, Nov 2005 Sub (2000-2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_47_39679=[""].join("\n");
var outline_f38_47_39679=null;
